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1 Introduction and Aim of the Study
The serotonin transporter (SERT) is a member of the solute carrier gene 6 (SLC6) familiy 
as also the dopamine transporter (DAT) and norepinephrine transporter (NET), that code 
the neurotransmitter sodium symporters (NSS) and other solute carriers. This group of 
transmembrane proteins is located on the presynaptic end of neurotransmitter emitting 
neurons. For rapid termination of neuronal transmission, substrate undergoes a reuptake 
into the emitting nerve cell, which is dependent on a gradient of sodium in the extra-
cellular space. Although these transporters are highly selective, they not only transport 
the  origin  substrate,  but  also  drugs  and  illicit  substances,  e.g.  amphetamines  and 
hallucinogens. Widely used therapeutics of the central nervous system (CNS) and abused 
drugs  target  the  SERT,  DAT  and  NET  to  inhibit  its  function,  e.g.  selective  serotonin 
reuptake  inhibitors  (SSRI),  tricyclic  antidepressants  (TCA),  selective  norepinephrine 
reuptake inhibitors (SNRI), methylphenidate (MPD), and psychostimulants like cocaine.
Due  to  the  lack  of  a  crystal  structure  of  the  neurotransmitter  sodium  symporters, 
computational methods such as homology modelling and docking are needed to predict 
the three dimensional structure of the protein and to reveal protein ligand interactions. 
Homology modelling is a probate method for investigations on proteins, where no crystal 
structures are available. Due to the increasing amount of biological and structural data 
and  the  increasing  performance  of  computer  technology,  the  precision  of  in  silico 
methods is rising.
The crystal structure of the bacterial leucine transporter (LeuT) from Aquifex aeolicus, in 
structure and function very homologue to the mammalian NSS, we chose as template for 
homology modelling. Docking usually is used for high throughput screening of putative 
new drugs in protein crystal structures. In the academic field, molecular docking is used 
to elucidate binding modes in either crystal structures or homology models.
The aims of the present study are to create a homology model of SERT, DAT and NET, to 
run docking with substrate and inhibitors on SERT and DAT, to hypothesize interactions 
and binding modes and to give suggestions for further mutations.
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2 Anatomy and Biology
The main tasks of the nervous system are the regulation of complex vegetative functions 
in  body,  coordinating  movements  and  mental  processes  and  processing  incoming 
environmental signals from the sense organs. This is basically effected in a binary, all-or-
none  manner  of  collecting  and forwarding excitatory and inhibitory signals  by single 
neurons over a network of billions of nerve cells.
In this chapter a short overview of the distribution of monoaminergic nerve fibres in the 
central nervous system (CNS) are given. We also shortly explain processes at the nerve 
terminals.
2.1 Monoamine Systems in Brain
Monoamines are small  active molecules,  which are acting as neurotransmitters in the 
brain  (Serotonin)  and  respectively  as  mediators  in  different  tissues  of  the  body 
(Histamine).  Therefore  they  are  very  important  for  the  highly  complex  physiological 
conditions. But they are also involved in pathological processes.
Figure 2.1: Neurones in the CNS (from S.H. Snyder, 1990)
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Serotonin (5HT)
The serotonergic cell bodies are predominantly located in the raphe nuclei in brain stem. 
They  project  to  almost  every  region  in  the  brain,  to  cerebral  cortex,  hippocampus, 
thalamus, basal ganglia, cerebellum and amygdala (Howell and Kimmel, 2008). Serotonin 
occurs in very low concentrations in the brain, but adopts multiple functions due to the 
high degree of differentiated receptors. The highest concentration of serotonin is found 
in  enterochromaffinic  cells  in  the  intestine.  In  the  periphery  it  acts  as  mediator  of 
inflammation by sensitising the nociceptors and takes also part in blood coagulation by 
activating platelets. Serotonin evinces cardiovascular activity. Depending on tissue and 
receptor subtype it effects vascular constriction or dilatation and positive inotropic effects 
(Siegel, 1994).
Figure 2.2 Serotonergic cell bodies are tightly located in the Raphe nuclei (blue). Their 
projections reach nearly each region in the human brain (from S. H. Snyder, 1990)
Gyrus cinguli
Cortex praefrontalis
Nucleus praeopticus
periaquaeductal
Grey
Bulbus olfactorius
Locus coeruleus
Raphe nuclei
Habenula
Thalamus
Hippocampus
Nucleus paraventricularis
Nucleus striaterminalis
Nucleus dorsomedialis
Corpus geniculatum
laterale
Cerebellum
Nucleus olivaris inferior
Area tegmentalis lateralis
Nucleus centralis amygdalae
Nucleus arcuatus
Nucleus supraopticus
Nucleus solitarius
3
Dopamine (DA)
The soma of dopaminergic neurons are located in the centre of the brain stem, called 
substantia nigra, which is part of the extrapyramidal system, ventral tegmental area and 
hypothalamus. A strong nerve tract projects to corpus striatum, which is coordinating 
arbitrary movements. Other projections draw to nucleus accumbens, nucleus caudatus, 
putamen,  to  mesolimbic  system,  prefrontal  cortex  and  amygdala.  Paracrine  excreted 
dopamin  influences  the  hypophysis  by  inhibiting  prolactine  excretion  (Howell  and 
Kimmel, 2008). In PNS, dopamin regulates blood supply of abdominal organs, especially 
of  kidney  and  is  also  found  in  postganglionic  sympathic  fibres  in  common  with 
norepinephrine. It has vasodilatative and sympathomimetic effects in peripheral vessels 
(Siegel, 1994).
Figure 2.3: Dopaminergic cell bodies are tightly located in Substantia nigra and Ventral 
tegmental area (blue), where they project to corpus striatum (from S. H. Snyder, 1990)
Corpus striatum
Putamen
Nucleus caudatus
Nucleus accumbens
Gyrus cinguli
Septum
Cortex praefrontalis
Tuberculum olfactorium
Pituitary gland
Corpus callosum
Substantia nigra
Cortex entorhinalis
Area tegmentalis
anteroventralis
Nucleus centralis amygdalae
Nucleus arcuatus hypothalamiMidbrain
central forebrain fascicle
Cerebellum
4
Norepinephrine (NE)
The norepinephrinic cell bodies are concentrated in the locus coeruleus and in the area 
tegmentalis. Similar to the projections of the serotonergic neurons, the axons project to 
nearly  each  region  in  brain,  as  to  the  cerebral  cortex,  ventral  tegmental  area, 
hippocampus,  thalamus,  hypthalamus,  nucleus  accumbens,  limbic  system,  cerebellum 
and amygdala. (Howell and Kimmel, 2008). Due to the innervation of the sympathicus by 
norepinephrine and epinephrine, there are fibres to medulla and spinal cord. In this role, 
it takes part on multiple roles in peripheral nervous system (PNS), such as cardiovascular 
effects, influencing heart beat and blood pressure, stress reaction and energy balance. 
High concentrations are found in andrenal medulla, lung and placenta (Siegel, 1994).
Figure 2.4: Norepinephrinic cell bodies are mainly located in the Locus coeruleus (blue). 
Their projections also reach nearly each region in the brain (from S. H. Snyder, 1990).
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2.2 Cell Membrane and Membrane Proteins
The  cell  membrane  is  organised  as  bilayer,  built  up  of  amphiphilic  phospholipid 
monomers. The hydrophilic phosphoric acid moieties of the monomers point towards the 
aqueous environment and the lipophilic tails of the fatty acids are orientated towards 
themselves. This organisation leads to a separation of the intracellular and extracellular 
compartment acting as a barrier of diffusion. There are integrated steroids and other 
lipids,  determining  the  characteristics  like  flexibility,  and  proteins,  that  facilitate  the 
transport  through the membrane, which is impermeable  for  large molecules,  charged 
compounds and ions. Due to the semipermeable property of the cell membrane, it acts as 
capacitor for the electrochemical potential, built up through the different osmolarities of 
the solute electrolytes in cytoplasm and liquor. The separation of charges between the 
extracellular and intracellular space acts as electrochemical force for building up action 
potentials and facilitating secondary active membrane transport (Siegel, 1994).
Membrane proteins are integrated in the phospholipid bilayer. The common properties, 
depending on function, are the lipophilic transmembrane domains (TMD), glycosylation 
and phosphorylations sites G-protein contact regions and ligand recognition sites on the 
intra- or extracellular domains, i.e. loop regions (IL, EL).
• Ion pumps build up and maintain the gradient of electrolytes by transporting their 
respective ion against the gradient through the cell membrane by using adenosin 
triphosphate (ATP). It is the electrochemical driving force for action potentials and 
secondary  active  transport.  They  are  also  involved  in  creating  and  forwarding 
action potentials.
• Receptors  proteins  are  the  lock  for  the  chemical  key  of  forwarding  the 
electrochemical  impulse  through  the  synaptic  cleft.  Ligand  binding  initiates  G-
proteins and accordingly enzyme activation.
• Ion channels are divided in ligand gated and voltage gated. Changes in membrane 
potential  due  to  an  action  potential  lead  to  an  opened  or  closed  channel. 
Accordingly ligands induce after binding also an open channel.
• Transporter  proteins  facilitate  the  passing  of  solutes,  like  glucose  and 
neurotransmitter,  through  the  cell  membrane.  This  form  of  transportation  is 
dependent onenergy and called secondary active transport.
(Siegel, 1994)
Transport  through  the  cell  membrane  for  impermeable  substances  is  mediated  by 
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transport  proteins.  Huge  volumes  are  transferred  by  endocytosis  (phagocytosis)  and 
accordingly exocytosis (liberation of neurotransmitters).
• Active transport is necessary, when solutes are not able to pass the membrane by 
diffusion  due  to  their  volume,  charge  or  an  existing  gradient.  Primary  active 
transport mechanism is coupled to ATP usage. Secondary active transport uses the 
prior built up gradient of electrolytes, where the substrates are coupled with.
• Passive transport does not need energetic effort. Free and facilitated diffusion are 
the two modalities. The simplest way crossing the membrane is diffusion, done by 
small  lipophilic  molecules.  Membrane  impermeable  substances  use  carrier 
proteins, called facilitated diffusion. Transport mechanisms of molecules occur as 
uniport, symport and/or antiport.
(Fain, 1999; Siegel, 1994)
from Rudnick, 2007
2.3 Neurotransmitters and Receptors
Neurotransmitters are the chemical factors that forward signals from one neuron to the 
next at the synaptic cleft. Synthesised in the cell corpus, they are packed to vesicles and 
transported along the neurotubuli  to the nerve terminals.  Release is  effected by Ca2+ 
mediated  exocytosis.  Chemically  they  are  derivatives  of  amino  acids,  purines  and 
peptides.  Functionally  there  are  grouped  to  excitatory,  inhibitory  and  modulating 
transmitters.  Each  transmitter  has  its  particular  receptor.  In  the  1920s  Otto  Loewi 
revealed, that the forwarding of the electrical impulse between two neurons is done in a 
chemical manner. Later, he discovered the first neurotransmitter, acetylcholine (Siegel, 
1994).
Figure 2.5a: Antiport Figure 2.5b: Symport
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Neurotransmitters can be divided due to their functional properties:
• γ-amino butyric acid (GABA) and glycine are the main inhibitory transmitter, by 
opening Cl- channels.
• Glutamate and aspartate are excitatory transmitters, acting at the NMDA, AMPA 
and kainat receptors
• Monoamines,  i.e.  catecholamines  (dopamin,  norepinephrine,  epinephrine), 
Serotonin  and  Histamine  are  modulating  transmitters  and  involved  in  multiple 
processes of the personality and regulation of peripheral systems
• Acetylcholine (ACh) coordinating the transmission on motor end plate, as well as in 
the  central  nervous  system  (CNS),  where  it  acts  in  the  cholinergic  system, 
important for synaptic plasticity, learning and reward.
• Endorphins, neuropeptides
• Adenosine, ATP and phosphoinositides
The receptors may appear in subtypes and are divided in three groups due to their 
biochemical property:
• The majority of the receptors are G-protein coupled. This G-protein is part of the 
cell signal transduction and activates enzymes, e.g. adenylylcyclase, phospholipase 
C, in the cytoplasm for creating 2nd messengers, like cAMP and IP3 to forward the 
signals.
• Ligand gated ion channels are another type of receptors. These proteins initiate 
and terminate action potentials by opening or closing the selective pore of their 
proper electrolyte. Another type of ion channel is the voltage gated ion channel, 
which is innervated in changes of the membrane potential.
• Enzyme  coupled  receptors  initiate  enzymatic  activity  after  ligand  binding,  e.g. 
tyrosine kinase.
(Löffler, 1999)
Figure 2.6: Cascade 
of signaltransduction 
(S. H. Snyder, 1990)
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Table 2.1 shows the neurotransmitter and their receptors, data not completed; + = stimulation; - = 
inhibition (Thews, Mutschler, Vaupel, 1999; Siegel 1994).
2.4 Synapse and Neuronal Transmission
Synapses are junctions between the terminal of one neuron with another nerve cell for 
discontinuous forwarding of excitation. There are different types of synapses described:
• Electrical synapses or gap-junctions are channel like connections of vicinal cells for 
a  rapid  exchange  of  information  and  small  substrates,  e.g.  amino  acids, 
nucleotides, glucose and ions, without innervation of a ligand-receptor-binding.
• Chemical synapses connect either two neurons or neurons with glands or neurons 
with muscles on the motor end plate.
(Fain, 1999)
Type Ion
A1-A3
D1, D5
D2-D4
A
B
NMDA
AMPA
mGlu1-mGlu7
Serotonin
DAG/IP3
P2X
P2Y
H1 DAG/IP3
H2
H3
Transmitter Receptor Amplifier second 
messenger
Adenosine G-Protein coupled
Epinephrine and 
Norepinephrine
α 1a-1d G-Protein coupled + phospholipase DAG/IP3
α 2a-2c G-Protein coupled - phospholipase DAG/IP3
β 1-3 G-Protein coupled adenylyl cyclase cAMP
Acetylcholine
Nicotinic Nmusc, Nneur Ion channel Na+
Muscarinic M1-M5 G-Protein coupled
Dopamine
G-Protein coupled adenylyl cyclase
G-Protein coupled adenylyl cylcase
γ-amino butyric acid
Ion channel Cl-
G-Protein coupled ion channels
Glutamate and 
Aspartate
Ion channel Na+
Ion channel Na+
Kainat Ion channel Na+
G-Protein coupled
Glycine
GlyRA Ion channel Cl-
GlyRB Ion channel Cl-
5HT
1 G-Protein coupled - adenylyl cyclase cAMP
5HT
2 G-Protein coupled + phospholipase
5HT
3 Ion channel Na+
5HT
4 G-Protein coupled + adenylyl cyclase cAMP
5HT
5
 - 5HT
7 G-Protein coupled
ATP-Receptors
Ion channel
G-Protein coupled
Histamine
G-Protein coupled + phospholipase
G-Protein coupled + adenylyl cyclase cAMP
G-Protein coupled autoreceptor
Endorphines and 
Opiates
μ 1-2 G-Protein coupled - adenylyl cyclase
κ 1-3 G-Protein coupled - adenylyl cyclase
δ 1-2 G-Protein coupled - adenylyl cyclase
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The commonly most known synapse is the chemical synapse, where one nerve terminal 
gets in contact with another nerve cell membrane. On the membrane surface different 
types of membrane proteins, e.g. receptors, ion channels, ion pumps, transporter are 
located, both on the presynaptic and the postsynaptic membrane.
Figure 2.7: Neuronal signal transmission in the synapse during firing:
PNT = Plasmamembrane Neurotransmitter Transporter
VNT = Vesicular Neurotransmitter Transporter
RNT = Receptors of NeuroTransmitters
E = Effector protein
(Masson et al., 1999)
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Due to the effect on the downstream neuron, synapses are distinguished in excitatoric 
and inhibitoric. In excitatoric neurons an action potential releases neurotransmitters, that 
induce a depolarisation in the following neuron by opening ligand gated Na+ channels. 
Inhibitoric neurons act  similarly,  with the difference of the involved ion. The released 
transmitters open ligand gated Cl- channels that leads to hyperpolarisation. Neurons are 
permanently  adding and subtracting currents of excitatoric or inhibitoric signals from 
their dendrites. After exceeding the threshold at the axon-hillock an action potential is 
generated. This is a temporary change in membrane potential of excitable cells as answer 
of an incoming stimulus. It is according to the all-or-none law, i.e. only after reaching and 
exceeding the stimulus threshold Na and K channels open and the depolarisation occurs 
completely. The action potential is forwarded over the axon or over electrical synapses 
and the affected membrane segments are turning into the refractory phase. After this 
step repolarisation to the resting potential  is done and the cell  is  ready for the next 
depolarisation (Mutschler, 2001; Fain, 1999; Siegel, 1994).
1. -70mV resting potential
2. opening postsynaptic Na+/Cl- and Ca2+ channels, ligand gated
3. -50mV; threshold, voltage gated Na+ channels open, depolarisation,
4. +50mV overshoot, voltage gated K+ channels open, repolarisation, Na+ channels close
5. -90mV hyperpolarisation by Na/K-ATPase, open K+ and Ca2+ channels - refractory phase
6. returning to resting potential for the next cycle
(Mutschler , 2001)
Figure 2.8c: IPSP coupled with 
Cl- inward and K+ outward 
currents
Figure 2.8a: EPSP coupled with 
Na+ inward an K+ inward currents
Figure 2.8b shows the 
reaching of an action 
potential.
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At  the  synaptic  cleft,  the  electrochemical  impulse  formed  by  an  action  potential  is 
converted to chemical information. In the presynaptic nerve terminal neurotransmitters 
are stored in vesicles. After an incoming action potential Ca2+ channels open and initiate 
the phosphorylation of synapsin, the anchoring protein of vesicles with cytoskeleton. This 
phosphorylation abolishes the connection of the vesicle with the cytoskeleton and is now 
able  to  move  to  the  cell  membrane.  Vesicles  carry  the  protein  synaptotagmin  that 
interacts with syntaxin located on the cell membrane. This interaction induces the fusion 
of vesicle membrane and axon membrane and further excretion of the vesicle contents. 
(Siegel, 1994)
After  fulfilled transmission,  the neurotransmitter  must  be removed from the synaptic 
cleft, in order to avoid further activation. The termination of signalling is done by the 
following ways:
• enzymatic, e.g. ACh-esterase decomposes the transmitter in the synaptic cleft for 
fast removement
• reuptake, e.g. 5HT is removed by a reuptake into the presynaptic neuron by a 
specific transporter
• thermodynamic,  where  the  transmitters  diffuse  from  the  synaptic  cleft  in  the 
extracellular fluid.
(Löffler, 2001)
Figure 2.9: Mechanism of exocytosis
(Fain, 1999)
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3 Pharmacology
In  this  chapter,  the  pharmacological  properties  of  selected  ligands  interacting  with 
monoamine transporters will be described. Due to their matter of interaction they can 
globally be divided in two groups: in substrates and inhibitors. The resulting effect is a 
direct elevation of the transmitter concentration in the synaptic cleft by initiating reversal 
transport activity and accordingly the indirect increase of transmitter by inhibiting the 
reuptake activity of the transporter. The NSS are target of a variety of therapeutics, like 
antidepressants, and illicit drugs, such as psychostimulants.
Monoamines
5-HT substrate of SERT
DA substrate of DAT and NET
NE substrate of DAT and NET
Amphetamines
MPD inhibitor of DAT and NET
MDMA substrate type releaser of SERT, DAT and NET
d-Amphetamine substrate type releaser of DAT and NET
Tropane alkaloids
Cocaine inhibitor of DAT, NET and SERT
CFT, CIT inhibitor of DAT, NET and SERT
Benztropine inhibitor of DAT, NET and SERT
Indole alkaloids
Psilocin substrate of SERT
DMT substrate of SERT
DIPT inhibitor of SERT
Ibogaine inhibitor of SERT
Toxines
MPP+ substrate type releaser of DAT, NET and SERT
Tyramine substrate of DAT and NET
Antidepressants
Desipramine inhibitor of NET
Fluoxetine inhibitor of SERT
Citalopram inhibitor of SERT
Table 3.1: Ligands of neurotransmitter:sodium symporter: divided into substrate and inhibitors 
(Rothman and Bauman, 2003)
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3.1 Serotonin / 3-(2-aminoethyl)-1H-indole-5-ol / 5-hydroxy tryptamine
Figures 3.1 a - c: Serotonin depicted in (a) 2D, (b) 3D and (c) with surface:
blue = hydrophilic, red = lipophilic, white = H-bond region 
(The following figures are depicted in a similar modality.)
5-HT is a biogenic amine with an indole base scaffold and a diethyl amino side chain. In 
the  1930s  serotonin  was  first  discovered  by  Vittorio  Erspamer  from  rabbit  gastric 
mucosa. He called the substance enteramine. Ten years later, Maurice Rapport, in the 
group  of  Irving  Page,  first  isolated  the  vasoconstricting  factor  in  blood  serum  and 
determined  the  chemical  structure.  In  the  early  1950s  it  was  recognised,  that  both 
substances,  enteramine and serotonin,  are identically.  (Whitaker-Azmitia  et  al.,  1999). 
During  the  last  70  years  serotonin  was  found  to  be  involved  in  a  wide  range  of 
physiological and pathophysiological processes. The physiological effects of serotonin in 
CNS effect mood, sleep, appetite, sleep, anxiety, fear, reward and aggresion (Howell and 
Kimmel, 2008). In PNS serotonin acts in blood coagulation, intestinal motility, pain and 
vascular  activity.  Serotonin is  also  implicated in  different  pathological  processes,  like 
migraine,  intestinal  disorders,  depression,  anxiety and also azheimer  disease  (Thews, 
Mutschler, Vaupel, 1999).
The biosynthesis of 5HT is effected by two enzymatic steps from the essential amino acid 
tryptophane. In the first step the aromatic indole ring is hydroxylated in position 5 and in 
the  second  step  the  decarboxylation  of  the  Cα atom  takes  place.  After  usage,  the 
decomposition of 5HT is effected by the enzymes MAO and aldehyde dehydrogenase to 
5-MeO-indole acetate (Jonnakuty and Gragnioli, 2008). Serotonin is also an intermediate 
in the biosynthesis of another hormone of the indol type, melatonin (Hardeland et al., 
2008).
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Figure 3.2: Biosynthesis and metabolism of Sertonin
3.2 Dopamine / 4-(2-aminoethyl)benzene-1,2-diol / 4-(2-aminoethyl) 
catecheol
Figures 3.3: Dopamine
Dopamine is a member of the catecholamines, as epinephrine and norepinephrine are, 
consisting  of  dihydroxylated  aromatic  base  scaffold  and a  hydroxylated  diethylamine 
sidechain. Arvid Carlsson discovered dopamin as main transmitter involved in movements 
and parkinsons disease in 1950s. Similar to the findings on serotonin, research on this 
neurotransmitter also elucidated a number of functions in human physiology, such as 
agonist in peripheric tissues, e.g. vessels in stomach, intestine and kidney, and as well as 
in  CNS.  Dopamine  is  also  involved  in  multiple  pathological  processes.  An  important 
pathological  process  is  the  parkinsons  disease,  where  the  dopaminergic  neurons  in 
corpus striatum, become poor of the transmitter. It also plays a role in schizophrenia, 
that is ascribed to an enhanced activity of the dopamine system in brain (Iversen and 
Iversen,  2006).  Due to the role in reward, dopamine plays an important role in drug 
addiction. The dopamine neurons in the mesolimbic system, which project to nucleus 
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accumbens and ventral tegmental area are involved (Nestler, from Madras 2006).
Biosynthesis  starts  at  the  precursor  L-tyrosin,  an  essential  amino  acid,  that  is 
enzymatically  converted  to  levodopa  by  hydroxylation  of  the  aromatic  ring.  After 
decarboxylation  dopamine  is  an  intermediate  of  the  further  biosynthesis  of 
norepinephrine and epinephrine. Epinephrine is found in small amounts in CNS. During 
the degradation two enzyme complexes are  involved for  hydroxylation and oxidation 
steps,  notably MAO and COMT,  converting  dopamine to vanillylmandelic,  as depicted 
below (Mutschler, 2001; Siegel, 1994).
Figure 3.4: Biosynthesis and metabolism of catecholamines
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3.3 Norepinephrine / (R)-4-(2-amino-1-hydroxyethyl)-1,2-
dihydroxybenzene / noradrenaline
Figure 3.5: R-Norepinephrine
Norepinephrine differs from dopamine in the hydroxylated sidechain, that builts a centre 
of chirality. So there exist two enantiomeres, the biologically active R-enantiomere and 
the isoform. In the 1940s Ulf von Euler discovered norepinephrine as neurotransmitter. 
Ten years later Julius Axelrod elucidated the mechanism of neurotransmitter reuptake on 
adrenergic  and  noradrenergic  nerves,  and  also  discovered  COMT  responsible  for 
catecholamine inactivation, see figure 3.4 (Goldstein et al., 2005; Torres et al., 2003).
This neurotransmitter is responsible for multiple effects in human body in the periphery, 
e.g. innervation of sympathetic fibres, blood pressure, heart frequency, and in CNS, e.g. 
attention,  learning,  sleep-wake-rhythm,  mood and locomotion.  Due  to  the  ubiquitous 
appearence of this mediator and neurotransmitter, different diseases are related to the 
norepinephrinic system.  It  is  supposed that  norepinephrine is  involved in depression, 
attetion  deficit  hyperactivity  disorder  (ADHD),  post  traumatic  stress  disorder  (PTSD), 
stress,  parkinsons  disease,  schizophrenia  and  autonomic  disorder  (Mutschler,  2001). 
Therapeutically it is used at anaphylactic shock, and also as adjuvant in local anaesthetic 
preparations (Pschyrembel, 2002).
3.4 Amphetamine / (RS)-1-phenylpropane-2-amine / "Speed"
Figure 3.6: R-Amphetamine
Amphetamine is built up of a benzene ring and an amino propion residue, which contains 
a  chirality  centre  in  Cβ that  lead  to  two  stereoisomeres.  It  is  a  synthetic  drug,  first 
synthesized in 1887, and was not found in nature. Due to the sympathomimetic effects, it 
was used as treatment of common cold, hay fever or asthma after its introduction in the 
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1930s.  In  1940s,  and  later  amphetamine  was  applied  for  different  diseases,  e.g. 
depression, narcolepsy, anti-obesity agent, until the addictive potential as well as misuse 
was observed in 1960s. In further consequence it was forbidden by law, and today it is a 
widely abused drug, as also its derivative methamphetamine. Abuse of these substances 
shows serious consequences on health and society, because of the addictive potential 
and damage on CNS. Only few preparations are on the market for treatment of ADHD and 
narcolepsy (Iversen, 2006).
The name amphetamine is  derived from  alpha-methylphenylethylamin and is  the lead 
substance and eponymous for a large group of compounds with similar structure and 
effects, called amphetamines (Shulgin and Shulgin, 1995). Due to the similar structure to 
dopamine  and  norepinephrine,  the  catecholaminergic  systems  in  CNS  are  primarily 
influenced by this drug. R-amphetamine is biologically more active than the L enantiomer. 
It  acts as indirect sympathomimetic by stimulating release of norepinephrine at nerve 
terminals  and  also  elevates  the  concentration  of  dopamine  in  the  synaptic  cleft  of 
dopaminergic  neurons  (Howell  and  Kimmel,  2008).  Amphetamine  is  a  substrate-type 
releaser  of  neurotransmitters,  i.e.  the  mechanism  of  increasing  catecholamine 
concentration is due to the inversion of transport direction of the vesicular monoamine 
transporters and also of DAT and NET. The affinity for SERT is about 100 fold lower 
(Rothmann and Baumann, 2003).
Table 3.2: Synthetic amphetamines and amphetamine like compounds biogenic analogues
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3.5 MDMA / 3,4-methylenedioxy-N-methylamphetamine / "Ecstasy"
Figure 3.7: R-MDMA
MDMA was first synthesised in the 1910s as intermediate in synthesis of haemostatic 
compounds.  It  was  first  described  as  psychotropic  drug  in  the  1960s  by  Alexander 
Shulgin. Ten years later it was used in common with MMDA by psychoterapists in clinical 
practice until the 1980s. In the late 1960s MDMA became popular under students and the 
consumption increased. Due to the increasing occurence abuse of this compound it was 
restricted by law in the mid 1980s (Iversen, 2006).
In CNS,  MDMA acts as substrate for  the NSS,  similar  to amphetamine. It  induces the 
inversion of transport direction of both the membraneous and the vesicular monoamine 
transporters. In contrast to D-amphetamine MDMA targets the SERT with higher affinity 
than DAT and NET (Rothman and Bauman, 2003).
3.6 Methylphenidate / α-phenyl-2-piperidinacetate methylester / Ritalin
Figure 3.8: R,R-Methylphenidate
Methylphenidate was first synthesized in the 1940s. The basic scaffold is similar to the 
amphetamines, but on the Cα atom there is connected a methylester group. This leads to 
two optical centres, which four enantiomeres. The R,R-D-threo form is the more active 
isoform and used for therapeutic purposes (Meltzer et al., 2002). The pharmacological 
effect differs from other amphetamines. In contrast to amphetamine and MDMA, which 
are substrate type releaser, MPD blocks DAT and NET with similar affinity (Iversen, 2006). 
On SERT the affinity is more than 200 fold lower (Rothman and Baumann, 2003). The 
pharmacological activity is similar to that of cocaine, but MPD does not lead to euphoria 
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and dependency, because of the slower onset (Swanson and Volkow, 2003).
The main area of application of MPD is the treatment of attention deficit hyperactivity 
disorder (ADHD). This disease has an incidence of 3 to 5 % with a multifactorial etiology. 
It is diagnosed in the first decade of life mainly on boys. Often their parents are also 
affected.  ADHD is a disorder in processing information and attention.  The concerned 
brain  regions are  the  frontal  lobe,  striatum and cerebellum where  the projections of 
norepinephrinic neurons are ending (Iversen, 2006; Biderman et al., 1999).
3.7 Cocaine / 3β-Hydroxy-1αH,5αH-tropane-2β-carboxylic acid-
methylester-benzoate
Figure 3.9: Cocaine
Cocaine is the psychostimulant factor in the South American plant erythroxylum coca. 
The leaves are used traditionally to increase work capacity and treat anoxia. The alkaloid 
was isolated in the 1860s by Albert Neiman. In Europe cocaine was added into beverages 
until the addictive potential became apparent. Since the 1970s cocaine became a widely 
abused drug with serious consequences of  the consuming individual  due to the high 
addictive potential (Madras and Lin, from Madras, 2006). In the beginning of the 20th 
century, it was first also applied as local anaestheticum, until more specific derivatives 
have been synthesised (Pschyrembel).
The neurochemical effects are the inhibition of the NSS and for that an indirect increase 
of serotonin, dopamine and norepinephrine in the synaptic cleft. It inhibits in ascending 
affinity SERT < DAT < NET (Rothman and Baumann, 2003). Cocaine is also a direct agonist 
on monoamine receptors, and inhibitior of Na+ channels in CNS.
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3.8 CFT / (-)-2-β-Carbomethoxy-3-β-(4-fluorophenyl)tropane (β-CFT, 
WIN 35,428)
Figure 3.10: CFT
A  number  of  derivatives  have  been  synthesised  in  the  research  on  DAT.  CFT  is  an 
analogue of cocaine and also a stimulant drug. It is primarily used for pharmacological 
experiments and radiolabeling studies due to the chemical stability (Kelkar et al., 1994; 
Kline et al., 1994). The neurochemical effect is similar to that of cocaine, by blocking the 
NSS in ascending order of affinity DAT < NET < SERT (Torres et al., 2003).
Figure 3.11 shows lead structures of cocaine analogues and DAT inhibitors (Rothman et al., 2008).
3.9 MPP+ / (1-methyl-4-phenylpyridinium)
Figure 3.12: MPP+
The precursor MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is converted by MAO 
B into its active, neurotoxic metabolite MPP+ (Javitch, 1985). MPTP is also an intermediate 
of  the  MPPP  (1-methyl-4-phenyl-4-propionoxypiperidin)  synthesis,  which  is  used  as  a 
synthetic opiate. MPP+ is transported by the NSS and causes a depletion of dopaminergic 
neurons in corpus striatum. By interfering with the neuronal mitochondria, the energy 
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production is disrupted. In further consequence the dopaminergic neurons die off and the 
Parkinsons disease is induced (Storch et al., 2004). Derivatives of pyridines are also used 
as "legal ecstasy". These compounds act similar to MDMA. Corrupted synthesis may lead 
to a precursor of MPP+ and exhibits a health risk of the illicit usage (Baumann et al., 
2005).
Table 3.3: Pyridines, Piperidines, Piperazines which show activity on NSS
3.10 Psilocin / N,N-Dimethy-4-Hydroxytryptamine
3.13: Psilocin
Psilocin is an indole alkaloid, first isolated in 1950s by Albert Hofmann from mushrooms 
of  Psilocybe  sp.,  which  were  used  as  hallucinogen  ritually  by  indigenous  peoples  in 
Mesoamerica. As indole alkaloid, the scaffold is very similar to serotonin. Psilocin acts as 
agonist  on serotonin receptors and as substrate at SERT. It  is the active form of the 
prodrug psilocybin, which is the main alkaloid in the Psilocybe species. After intestinal 
absorption,  psilocybin  acts  potent  hallucinogenic  drug.  The  dephosphorylation  of 
psilocybin leads to psilocin, which is also highly active (Schultes and Hofmann, 1998).
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Figure 3.4: Indole alkaloids
3.11 DMT/ N,N-Dimethyltryptamine
Figure 3.14: DMT
N,N-DMT was discovered in plants growing in the Amazon rainforest, and also in the 
mucus of the toad, Bufo bufo. Orally applied, DMT is rapidly eliminated by MAO in the 
liver and thereby looses the efficacy. Indigenous peoples in South America use a decoct of 
DMT  containing  leaves  and  the  bark  of  a  liana  containing  beta-carbolines  as 
hallucinogenic drug, which is called ayahuasca. Beta-carbolines act as inhibitor of MAO 
that makes DMT available orally (Schultes and Hofman, 1998). It is a highly active agonist 
on 5HT receptors and acts also as substrate on the SERT (Nonaka et al., 2007, Adkins et 
al., 2001).
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 4 Pharmacoinformatics
In history, modelling of chemical structures and macromolecules was and nowadays still 
is important for imagination and understanding. As the comutational power is rapidly 
rising, computers are getting more and more important for simulating and predicting in 
multiple  fields  (Böhm,  Klebe,  Kubinyi,  1996).  In  the  field  of  pharmacoinformatics, 
modelling  of  proteins  for  simulations  like  docking  is  useful  to  elucidate  information 
about the interaction of proteins with ligands. With the also rapidly increasing amount of 
biological data, such as mutagenesis data, protein sequences and crystal structures, and 
with  the  empirical  knowledge  of  the  behaviour  of  proteins,  in  silico  simulations  are 
getting more precise (Rauhut, 2001). Today, pharmacoinformatic methods are used for 
screening  libraries  of  organic  substances  to  test  each  compound  for  their  drug-like 
potential or to find derivatives of known drugs for more specific effects and reducing side 
effects (Rauhut, 2001; Steger, 2003). It is the first step in the cue of finding hits and 
leads.  There  are  used  ligand  based  methods,  like  quantitative  structure  activity 
relationship (QSAR), comparative molecular field analysis (CoMFA), and structure based 
methods, such as homology modelling and docking (Böhm, Klebe, Kubinyi, 1996). In this 
study we focus on structure based methods.
 4.1 Structure of Proteins
The structure of a protein determines its proper function. Neurodegenerative diseases, 
such  as  Creutzfeldt  Jakob disease  and also  Alzheimer  disease,  are  due  to misfolded 
proteins. It is still not clear, how a protein finds its correct three dimensional structure 
only from its primary sequence. Natures algorithm of protein folding is depending on 
different  forces and interactions of the single amino acid and the environment (Lesk, 
2001). Until now, it is not possible to predict the three dimensional, tertiary or quaternary 
structure of a protein only from its primary amino acid sequence (Lesk, 2003; Steger, 
2003; Rauhut, 2003).
 4.1.1 From Gene to Protein
"Proteins are, where the action is" (Lesk, 2001). They fulfill  lots of different structural 
(cytoskeleton)  and functional  (enzymes)  functions  in  organisms.  The  building  plan  is 
coded in the DNA in the cell nucleus by using the four nucleotides A, C, G, T. Each of the 
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20 canonical amino acids, localised in cytoplasm, is coded in a more or less distinct three 
letter  code  of  nucleotides  on  the  mRNA.  At  the  ribosomes,  the  primary sequence  is 
synthesised by connecting the carboxyle moiety with the amino group of the following 
amino acid. The folding takes place immediately and is supported by chaperones. After 
growing from primary to tertiary or quaternary structure, post translational processes like 
glycosylation are done in the Golgi apparatus (Löffler, 2001, Lesk, 2001).
Figure 4.1: Connection of amino acid at the back bone scaffolds peptides
Proteins are macromolecules that are built up of monomers. These chemical bricks are 
the 20 proteinogenic amino acids. They can be clustered in different ways due to their 
structure, their physical and chemical properties and their charge (see figure 4.2). All of 
them are alpha amino carbonic acids with a side chain on the Cα, except the simplest 
member glycine. This property turns the compounds asymmetric, from which nature uses 
only the L form for building up proteins. Another exceptional amino acid is proline, where 
the side chain forms a ring from Cα to the amino group. Non-canonical amino acids result 
from  modifications  after  the  synthesis  of  the  protein  or  during  metabolism,  e.g. 
selenocysteine, ornithine, pyrrolysine, hydroxyproline (Steger, 2003).
Figure 4.2: Amino acids clustered by physicochemical and steric properties (Steger, 2003).
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The hierarchy of the protein architecture starts at the single amino acid and the further 
resulting linear amino acid sequence. This is called the primary structure of proteins. 
Each of the residues is characterised by its physicochemical properties. In the collectivity 
of  all  concatenated monomers,  it  leads to distinct  properties of  the protein.  Multiple 
forces and interactions, such as Van-der-Waals interaction, hydrogen bonds, hydrophobic 
interaction,  salt  bridges and disulphide bonds within the conglomerate  influence  and 
keep the substructures stable and the protein functionable (Lesk, 2001; Löffler, 2001). 
The connection between vicinal amino acid is called peptide bond. It is a planar amide, 
defined by the angle ω, with rotable bonds to Cα and C', defined by the angles Φ, Ψ and χ. 
This planarity limits the degrees of freedom for the protein backbone. During the folding 
process, proteins follow a defined geometry concerning the two angles  Φ and  Ψ.  The 
Ramachandran plot  depicts both angles in atwo dimensional coordinate system (Lesk, 
2001; Steger, 2003).
Figure  4.3  shows  the  characteristic  bond 
lengths  and  angles  of  the  planar  peptide 
bond (Steger, 2003).
Figure 4.4: The grey surface displays the planarity of 
the  peptide  bond  and  the  four  torsional  angles 
characterise  the  geometric  properties  of  the  Ca 
refered to the neighbours:
Φ: Cα to amide N (x-axis in ramachandran plot)
Ψ: Cα to carbonyle C (y-axis in the phi-psi-plot)
χ: Cα to Cβ of the residue (angle of the rotamer)
ω: angle of the amide (ω = 1, due to planarity)
(Steger, 2003)
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Figure 4.5: Regions of secondary structures in the Ramachandran plot (Petsko and Ringe, 2004)
Figure 4.6: Parameters of secondary structures (Lesk, 2001)
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Figure 4.7: (a) Parameters of α helices; (b) Antiparallel β strand (Steger, 2003)
Peptides are chains of few amino acids. Small peptides are linear and flexible chains of 
amino acids. Polypeptides can be organised to repeating structural elements, which are 
called  secondary  structure.  In  a  protein,  the  three  dimensional  organisation  is 
distinguished  in  the  often  appearing  α helix,  and  the  β strand.  Depending  on  the 
interactions between proximal neighbours helices are subdivided in 3.10 helix,  π helix 
and β helix as well as the β strand appears in distinct structures, i.e. the β bulge and the β 
barrel. Proteins also contain characteristic three dimensional structures, which are called 
super secondary structure, e.g.  α and  β hairpin, helix-turn-helix motifs, coiled-coil helix 
(Lesk, 2001; Steger 2003).
The third hierarchy in protein architecture is the tertiary structure, which is the finally 
folded three dimensional structure of a protein chain or a single protein. Stable and fully 
functional  substructures  of  proteins  are  called  domains.  Forces  and  interactions 
mentioned above fix the protein or the domains in the stable and functional morphology, 
such as covalent disulphide bonds between two cysteines, salt bridges between acidic 
and  basic  residues  and  the  weaker  interactions  like  hydrogen  bonds,  hydrophobic 
interactions and Van-der-Waals interactions. Proteins and the side chains are moving and 
interacting with the surrounding medium as well as residues interact among each other.
The quaternary structure is the fully developed protein with its coupled domains and 
feasible  glycosylations.  It  is  the  unit  which  fulfils  multiple  tasks  in  cells  of  living 
organisms.
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 4.1.2 Structure Analysis
If  no  crystal  structure  of  a  protein  is  available,  biochemical,  pharmacological  and 
computational  methods are  combined to reveal  information about  the structure.  It  is 
hypothesised  that  identical  or  homologous  sequences  give  similar  three  dimensional 
structure (Rauhut, 2001). Sequenced proteins and known structures are stored in free 
accessible  databases,  e.g.  the  protein  data  base  (www.rcsb.org).  Multiple  tools  for 
homology searching and alignments are available, see table 4.1(Lesk, 2001).
Biochemical assays and physical methods are done for elucidating the three dimensional 
structure and the function of proteins:
• Site  directed  mutagenesis:  By  changing  one  or  more  codons  in  the  gene  and 
transferring the DNA in an expressing cell by a viral vector, the mutated protein is 
expressed.  The  following  experiments  elucidate,  how capacious  the  mutations 
change the function of the protein compared to the wild type.
• Cysteine scanning: Single or multiple mutations from the original amino acid to 
cysteines are done.  The cysteines are targeted by reactive  agents containing a 
sulfhydryl  moiety  (MTS-reagents:  MTSET,  MTSES,  MTSEA).  These  experiments 
envice the localisation of the mutation, in particular at membrane proteins and is 
also  called  SCAM-method.  Cross  linking  with  bifunctional  MTS  reagents  gives 
information about distances between the reaction partners.
• Alanin  scanning:  Mutation  of  residues  to  alanine  elucidate  the  functional 
importance  of  the  residue.  The  workflow  is  similar  to  the  cysteine  scanning 
method.
• Species scanning mutagenesis: Building chimeras of similar proteins from different 
species may show differences in functionality and selectivity.
• Engineered Zn and Cd binding sites: Only few amino acids (His) interact with Zn 
ions.  This  method  is  used  to  elucidate  the  proximity  of  specific  residues  or 
domains.
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Spectroscopic methods deliver precisely the three dimensional structure:
• The X-ray diffraction is the commonly used method to get exact information about 
the  three  dimensional  structure  of  a  protein.  It  is  highly  sophisticated  in 
preparation an analysis. The principle is, to irradiate a crystallised protein with X-
rays. From the angels of scattering and interferences, the shape of the atoms can 
be recalculated. Depending on the method, the resolution ranges from 3.5 to 0.7 
Å. At high the resolution it is possible to localize the electronic sheath of each 
atom, including the often bound water molecules and ions. The crystal structure of 
a protein is a snap shot of an energetic favourable state for the crystal. Information 
of domain movements can not  be obtained based on the conformation of  one 
crystal.
• With NMR spectroscopy, the disadvantage of only having a single and rigid snap 
shot, can be abolished. It is predominantly used for peptides and small proteins. In 
recent  years,  progress in this  field allows to analyse bigger  proteins  and even 
membrane proteins.  The advantage of this method is to get  information about 
protein  domain  movements,  protein-protein  interactions  and protein-membrane 
contacts.
Figure 4.8: Structures in the protein database (annual report of the pdb, 2007);
* data not completed for 2007 (www.rcsb.org).
*
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Table 4.1: WorldWideWeb adresses for homology search, alignment and modelling tools;
P = Programm, S = Server (Martí-Renom et al., 2000)
Name Type
Databases
CATH S
S
S
MODBASE S
PDB S
PRESAGE S
SCOP S
S
Template search
123D S
BLAST S
DALI S
S www2.ebi.ac.uk/fasta3
MATCHMAKER P
PHD, TOPITS S
PROFIT P
THREADER P
UCLA-DOE, FRSVR S
Sequence alignment
BCM SERVER S
BLAST S
BLOCK MAKER S
CLUSTAL S
FASTA3 S www2.ebi.ac.uk/fasta3/
MULTALIN S
Modelling
COMPOSER P
CONGEN P
CPH models S
DRAGON P
ICM P
P
MODELLER P
MOE P
LOOK P
QUANTA P
SYBYL P
SCWRL P
SWISS-MOD S
WHAT IF P
Model evaluation
ANOLEA S
AQUA P
S
ERRAT S
PROCHECK P
P
P
PROVE S
SQUID P
WorldWideWeb address
www.biochem.ucl.ac.uk/bsm/cath/
GenBank www.ncbi.nlm.nih.gov/GenBank
GeneCensus bioinfo.mbb.yale.edu/genome
guitar.rockefeller.edu/modbase/
www.rcsb.org/pdb/
presage.stanford.edu
scop.mrc-lmb.cam.ac.uk/scop/
SWISSPROT+TrEMBL www.ebi.ac.uk/swissprot
www.lmmb.ncifcrf.gov/nicka/123D.html
www.ncbi.nlm.nih.gov/BLAST/
www2.ebi.ac.uk/dali/
FastA
bioinformatics.burnham-inst.org
www.embl-heidelberg.de/predictprotein/predictprotein.html
www.came.sbg.ac.at
globin.bio.warwick.ac.uk/jones/threader.html
www.doe-mbi.ucla.edu/people/frsvr/frsvr.html
dot.imgen.bcm.tmc.edu:9331/
www.ncbi.nlm.nih.gov/BLAST
blocks.fhcrc.org/blocks/blockmkr/make_blocks.html
www2.ebi.ac.uk/clustalw/
pbil.ibcp.fr/
www-cryst.bioc.cam.ac.uk
www.congenomics.com/congen/congen.html
www.cbs.dtu.dk/services/CPHmodels/
www.nimr.mrc.ac.uk/mathbio/a-aszodi/dragon.html
www.molsoft.com
InsightII www.csc.fi/english/research/software/insightii
guitar.rockefeller.edu/modeller/modeller.html
www.chemcomp.com
www.mag.com
scv.bu.edu/documentation/software-help/scientific-engineering/quanta.html
www.tripos.com
www.cmpharm.ucsf.edu/bower/scrwl/scrwl.html
www.expasy.ch/swissmod
www.sander.embl-heidelberg.de/whatif/
www.fundp.ac.be/pub/ANOLEA.html
www-nmr.chem.ruu.nl/users/rull/aqua.html
BIOTECHd biotech.embl-ebi.ac.uk:8400/
www.doe-mbi.ucla.edu/erratserver.html
www.biochem.ucl.ac.uk/roman/procheck/procheck.html
ProCeryone www.proceryon.com/
ProsaIIe www.came.sbg.ac.at
www.ucmb.ulb.ac.be/UCMB/PROVE
www.yorvic.york.ac.uk/oldfield/squid
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 4.2 Homology Modelling
Homology modelling is  the computational  method to predict  the tertiary structure of 
proteins. Two different approaches in homology modelling are available, where the ab-
initio or de novo method is done by calculating the global free energy minimum.  The 
three dimensional protein folds are modelled only from the amino acid sequence (Moult, 
2005). In contrast, the comparative modelling uses templates of homologous proteins, 
which is the more accurate method (Baker et al., 2001; Martí-Renom et al., 2000). Due to 
the enormous effort necessary to get a protein crystallized, homology modelling is an 
accurate  method  for  research  on  proteins.  The  cue  of  creating  homology  models  is 
divided in four steps: finding homologous structures, aligning the sequence, creating the 
model and validating the model (Baker, 2001).
Figure 4.9: Workflow of homology modelling (Marti-Renom et al., 2000)
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 4.2.1 The Alignment
The higher the sequence identity the higher the accuracy of the model is. But also the 
sequence homology is an important factor in molecular modelling. In this case residues 
with similar chemical characteristics can be treated as "identical". Different algorithms for 
sequence alignment are available (Rauhut, 2001; Martí-Renom et al., 2000). The first step 
in the cue of homology modelling is finding templates for the query structure by using 
sequence  comparison  methods,  such  as  PSI-BLAST  (www.ebi.ac.uk/Tools/psiblast). 
Another way of alignment is a sequence-structure comparison. In this case, the fold of a 
protein is compared, which is called fold recognition (Baker et al., 2001; Lee et al., 2007).
Figure 4.10: Example of an alignment (Beuming et al., 2006)
 4.2.2 The Template
An important step towards a good homology model is a good template. A high degree of 
both structural homology and function, a high quality model will result. In many cases the 
template is a crystal structure taken by X-ray structure analysis. A high resolution of the 
crystal structure also elevates the quality of the model. There are also NMR-data used for 
creating models. The advantage of NMR spectra is that movements of the protein and the 
residues get visible. Molecular dynamic simulation and energy minimization calculations 
can be  done with  higher  precision,  if  protein movements  are  known.  But  it  is  still  a 
challenge to get NMR spectra of huge proteins or of membrane proteins (Lee et al., 2007; 
Martí-Renom et al., 2000)
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 4.2.3 The Model
In  principal,  comparative  homology  modelling  superposes  conserved  residues  on  the 
coordinates of the template. Differing residues are changed on basis of the Cα atoms of 
the protein backbone. An indicator for the precision is the root mean square deviation 
(RMSD), which is the spatial deviation of query protein from the template. At a sequence 
identity of more than 50 %, the RMSD between the model and the template is about 1 
Ångström (Å, 1 Å = 10-10 m = 100 pm), which approximates medium resolution X-ray 
structures.  The  error  is  due  to  different  orientations  of  the  side  chains.  When  the 
sequence identity ranges from 30 to 50 %, the RMSD increases to 1,5 Å based on the 
backbone atoms and modelled loops. A sequence identity of lower than 30 % the error as 
well as the RMSD increases very rapidly (Baker et al., 2001; David et al., 2005).
Figure 4.11: Correlation of sequence 
identity and accuracy of structure 
prediction (Marti-Renom et al., 2000)
Multiple methods and programs are available for creating homology models (Marti-Renom 
et al., 2001). The necessary calculations for building the homology model in silico are 
done in forcefields parameterised for proteins. These forcefields are gained empirically 
due  to  the  increasing  knowledge  about  the  behaviour  of  the  proteins.  During  the 
modelling process energy minimizations based on a rotamer library are done to avoid 
clashes of residues. This leads to slight movements in the backbone and also the side 
chains. Conserved residues or protein regions are calculated exactly, since they act as 
anchor  point  during  the  modelling.  The  loop  folding,  due  to  their  high  degree  of 
flexibility, still  is  quite difficult  to calculate. They are modelled by using loop folding 
databases (Al-Lazikani et al., 2001).
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 4.2.4 Refinement and Validation
Up to now, there are no reliable procedures for evaluating protein homology models. 
Different  programs  are  available,  considering  steric,  geometric  and  energetic  criteria 
(Petrey and Honig, 2005; Dunbrack et al., 2006). Depending on the software package, 
energetic functions, such as electrostatic solvation energy and H-bonding are calculated. 
For evaluation of the protein model, protein geometry tools, such as the Ramachandran 
plot can be used. A good parameter are the amount of clashes between residues. On the 
other  hand  the  model  can  be  compared  with  evident  biological  data,  such  as 
characteristic regions or binding sites (MOE).
 4.3 Docking
Docking can be done with small ligands and also proteins. In this study, we concern small 
ligand docking,  which is  the prediction of  ligand orientation in the binding site  of  a 
protein. It was pioneered in the early 1980s and now docking and virtual screening is an 
important method in drug discovery for hit finding and lead optimisation. The aim is to 
get structural information for describing interactions and for predicting activity. Multiple 
software packages are now available  for  this  multistep procedure and allow different 
consideration of the interaction partners (Kitchen et al., 2004; Leach et al., 2006).
Table 4.2: Docking software and features
docking program algorithm ligand treatment protein flexibility
genetic algorithm stochastic
CDOCKER grid based MD simulation simulation
DOCK incremental, simulation
incremental systematic
incremental
FLOG database
Glide Monte Carlo incremental
GOLD genetic algorithm stochastic systematic
Hammerhead simulation
ICM Monte Carlo
MCDOCK
MDD Monte Carlo
MOE-Dock stochastic none
PRO_LEADS stochastic
QXP Monte Carlo
AutoDock
FlexE
FlexX
Surflex
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 4.3.1 The Ligand
Chemical structures have a continuous intramolecular movement due to the degrees of 
freedom of certain chemical bonds. To consider these movements during the docking 
process, multiple conformers of the ligand must be created. Different approaches are 
possible to allow ligand flexibility:
• Systematic  methods:  The  systematic  search  forces  to  explore  all  degrees  of 
freedom of a molecule. Another method is the incremental one, where the ligand is 
divided into rigid and flexible fragments. After that, it is rebuilt based on the rigid 
core. Conformational databases are also used for rigid docking, i.e.  during the 
docking process the ligand is treated rigid.
• Stochastic methods: This method makes random changes of the ligand by using 
Monte Carlo methods, genetic algorithms or the tabu search.
• simulation  methods:  Molecular  dynamic  simulation  is  a  popular  approach  for 
creating conformers of ligands. In this approach, the molecule is virtually heated. A 
problem is, that this method cannot cross high energy barriers and therefore the 
compound might accommodate in local minima of the energy surface.
(Kitchen et al., 2004)
 4.3.2 The Site
As well established, the principle of protein ligand interaction seems like the lock and key 
principle. In physiological conditions, the ligand approximates its receptor by multiple 
forces, such as electrostatic energies, H-bonds and Van-der-Waals interactions. When the 
ligand reaches its receptor, an adaptation of both the receptor and the ligand takes place 
(Kubinyi,  1996).  For  this  reason  not  only  ligand  flexibility,  but  also  the  side  chain 
movements of the protein must be considered, which is still  challenging. Most of the 
docking  programs  treat  the  receptor  nearly  rigid.  For  considering  receptor  flexibility 
different approaches are available:
• molecular dynamic simulations
• Monte Carlo calculations
• rotamer libraries and
• dead-end elimination algorithms
(Kitchen et al., 2004).
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Before starting the docking run, the binding site should be defined. In the present study 
we  defined the  biologically  important  interaction partners  which  are  known from the 
literature by both site directed mutagenesis and docking studies.
 4.3.3 The Placement
The placement is the positioning of the ligand in the binding site. This is  calculated with 
different  methods.  Depending  on  the  algorithm,  the  following  methods  can  be 
distinguished:
• Forcefield based methods consider ligand flexibility as well as protein, i.e. binding 
site flexibility by using molecular dynamic simulation or Monte Carlo algorithms. 
These methods perform most accurately.
• Evolutionary  methods  create  sets  of  different  ligand  conformers  called 
chromosome,  where  the  single  genes  are  parameters  such  as  angles  between 
vicinal  atoms of the molecule.  By mutations of single genes, new chromosome 
populations  are  generated.  In  the  group  of  evolutionary  methods  are  genetic 
algorithms, evolutionary programming and tabu search.
• Fragment based or incremental methods split the ligand into fragments. The first 
fragment should have anchoring features on which the ligand is built up in the 
binding site.
• Shape complementary based methods estimate the shape of both, the ligand and 
the binding site. After evaluation of both shapes, the best fit is estimated on basis 
of energetic energy terms, such as Van-der-Waals interaction surface.
• Hybrid  methods  combine  the  previously  mentioned  methods  to  improve  the 
accuracy of docking.
(David et al., 2005)
 4.3.4 Scoring and Ranking the Poses
After the docking run up to thousands of poses are generated. Scoring functions evaluate 
the docked poses on basis of energetic values as combination of entropic and enthalpic 
effects or other parameters such as distances. Each docking programm can be combined 
with each scoring function. Finally the most favourable poses should be ranked first by 
estimating parameters such as binding affinity, binding mode or biological activity. The 
scoring functions as well can be divided in groups depending on the algorithm that is 
used:
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• Forcefield based scoring functions end up and quantify docking poses in the sum 
of energy terms, e.g. Van-der-Waals interaction energy, electrostatic energy and 
geometrical  parameters.  They  consider  receptor-ligand  interactions  as  well  as 
internal ligand energies.
• Empirical  scoring  functions  should  reproduce  experimental  data  like  binding 
conformations or energies. They are obtained by a sum of uncorrelated terms due 
to  regression  analysis.  These  terms  are  elucidated  from  crystal  structure 
information or experimentally determined binding energies.
• Knowledge based scoring functions reproduce experimental structures
• Shape based scoring functions are calculated simply and often act as primary filter 
in the scoring cascade.
• Consensus scoring as combination of different scoring functions.
(Kitchen et al., 2004; David et al., 2005)
It is still difficult to get the most accurate pose only on basis of scoring functions. In 
contrast to docking into crystal structures or homology models, the prediction of activity 
or binding affinity is quite challenging. Because in vivo there is a multitude of forces 
present, which are highly complicated to calculate (Leach et al., 2006).
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5 Neurotransmitter:sodium symporter
In this chapter we will give a description of structural elements of SERT and DAT, and also 
of the template LeuT. These membrane proteins share common features like the sodium 
dependency of transport action, the similar three dimensional structure of 12 TMDs and 
conserved regions in the substrate translocation pathway, including the binding site.
This type of membrane proteins, the solute carriers, facilitate the penetration of the cell 
membrane  for  charged organic  molecules,  that  are  not  able  to  diffuse  through.  The 
driving force is an osmotic gradient built up by Na/K-ATPases. They are ubiquitous in 
prokaryotes  and  eukaryotes  and  passably  homologous.  Recently,  investigations  have 
been done on the bacterial amino acid transporters Tyt1, a selective tyrosine transporter 
expressed  in  Escherichia  coli  (Quick  et  al.,  2006)  and  TnaT,  a  selective  tryptophane 
transporter expressed in Symbiobacterium thermophilum (Androutsellis-Theotokis et al., 
2003; Zomot et al, 2007), which are also structural and functional homologues of LeuT
Today, more than 300 known transport protein families are classified and accessible in 
the  transport  classification  database  from  the  University  of  California,  San  Diego 
www.tcdb.org. (Saier et al, 1999). The taxonomy of the transporter classification system 
(TC-System) is:
• class, determined by the mode of transport and energy coupling mechanism
• subclass, type of transporter and energy coupling mechanism
• family or superfamily
• phylogenetic cluster within a family
• substrate specifity
The neurotransmitter:sodium symporter are classified in:
• class 2 - electrochemical potential-driven transporters
• subclass A - porters (uniporters, symporters, antiporters)
• family 22 - neurotransmitter sodium symporters
coded in a five digit TC-number. Table 5.1 lists the classified members of the NSS family:
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5.1 The Leucine Transporter from Aquifex aeolicus
The Leucine transporter (LeuT) is a homologous transmembrane transport protein of the 
mammalian NSS. It  transports the amino acids leucine and alanin with higher affinity 
through the bacterial membrane driven by the sodium gradient in the cytoplasm (Shi et 
al.,  2008).  In  2005,  the crystal  structure  of  the bacterial  amino acid  transporter  was 
published.  The  crystallized  transporter  from Aquifex  aeolicus  (LeuT,  pdb code  2A65, 
www.rcsb.org, swiss prot ID O67854) has bound its substrate leucine in the centre of the 
protein, two sodium ions near the substrate binding site, one chloride ion, five detergent 
molecules  and  210  water  molecules.  The  resolution  is  at  1.65  Å  and  shows  the 
transporter  in  the  substrate  occluded  state.  For  substrate  translocation,  LeuT  must 
change its conformation. It is supposed that the transporter appears in three positions, 
standing in equilibrium.
• outward faced, where sodium and substrate can bind
• the occluded state, where substrate is bound (X-ray structure in the pdb)
• inward faced, where leucine and the two sodium ions are being released.
(Yamashita et al., 2005).
TC-Code Name Abbreviation Organism
2.A.22.1.1 Serotonin transporter SERT P31645
2.A.22.1.2 Norepinephrine transporter NET P23975
2.A.22.1.3 Dopamin transporter DAT Q01959
2.A.22.1.4 Dopamin transporter T23G5.5 Q03614
2.A.22.2.1 PROT
2.A.22.2.2 Glycine transporter GlyT1c
2.A.22.2.3 B0+
2.A.22.2.4 Neutral amino acid transporter CAATCH1
2.A.22.2.5 Neutral amino acid transporter KAAT1
2.A.22.2.6 Glycine transporter GlyT2b
2.A.22.2.7 O76689
2.A.22.2.8 nutrient amino acid transporter AAT1 AAR08269
2.A.22.2.9 BAG39453
2.A.22.3.1 P48065
2.A.22.3.2 GABA transporter GAT-1 P50531
2.A.22.3.3 P31641
2.A.22.3.4
2.A.22.3.5 CRT P28570
2.A.22.3.6 GABA transporter GAT-1 AAT02634
2.A.22.4.1
2.A.22.4.2 O67854
2.A.22.5.1 MJ1319
2.A.22.5.2 Tyrosine transporter Tyt1 Q8RHM5
2.A.22.6.1 SIT1 Q64093
2.A.22.6.2 Neurotransmitter transporter NTT4 P31662
2.A.22.6.3 Neutral amino acid transporter B0AT1 Q695T7
swissprot-
code
Homo sapiens
Homo sapiens
Homo sapiens
Caenorhabditis elegans
Proline transporter Rattus norvegicus
Rattus norvegicus
Neutral and cationic amino acid 
transporter Homo sapiens
Manduca sexta
Manduca sexta
Mus musculus
Acetylcholin and choline transporter Snf-6 Caenorhabditis elegans
Aedes aegypti
Densovirus type-2 receptor Nsd-2 Bombyx mori
Betaine and GABA transporter Homo sapiens
Homo sapiens
Taurine transporter Taurine Homo sapiens
Creatine transporter Creatine Oryclologus cuniculus
Creatine transporter Rattus norvegicus
Caenorhabditis elegans
Tryptophan transporter TnaT
Symbiobacterium 
thermophilum
Leucine transporter LeuTAa Aquifex aeolicus
Hypothetical Na+-dependent permease Methanococcus jannaschii
Fusobacterium nucleatum
Proline transporter Rattus norvegicus
Rattus norvegicus
Homo sapiens
Table 5.1: Members of the Neurotransmitter:Sodium Sympoerter Family, from www.tcdb.org (Quick, 2002)
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In  2007,  crystal  structures  of  LeuT  with  bound  TCAs  were  published.  Due  to  the 
conserved residues near the bound TCA, these structures revealed the putative binding 
pocket of antidepressants on the SERT, DAT and NET (Singh et al., 2007, Zhou et al., 
2007,  pdb-codes  2Q6H,  2Q72,  2QB4,  2QEI,  2QJU).  The  co-crystallized  TCAs  are 
clomipramin,  imipramin  and  desipramin.  One  of  the  crystals  has  bound  alanin  as 
substrate (pdb-code 2QEI). These structures reveal a second binding pocket, outside of 
the  extracellular  gate,  where  substrate  is  supposed  to  be  bound  (Shi  et  al.,  2008; 
Rudnick, 2007).
Figure 5.1: The transportation cycle of LeuT, from Yamashita et al., 2005
Figure 5.2: The extracellular vestibule of LeuT with the bound TCA 
desipramin, pdb-code 2Q72
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Structure and Function (from Yamashita et al., 2005)
LeuT, as bacterial homologue of the mammalian NSS, shows a certain degree of identity 
with the monoamine transporters. Also the length, the three dimensional structure and 
the  transport  action  is  supposed to  be  similar  all  over  the  NSS  family.  The  primary 
sequence of LeuT consists of 519 amino acids with a formula molecular weight of about 
58,1 kDa (www.rcsb.org). They are organized to 12 TMDs with transporter dimensions of 
70 Å through the membrane and 48 Å in diameter.
The extracellular face consists of 3 markable loops. EL2 which connects TM3 and TM4, 
rises furthest into the extracellular space. EL4, connecting TM7 and TM8, and EL2 are 
composed of α helical segments. EL3 has a helix and two short β strands and is located 
between TM5 and TM6. The two helical segments of EL4 point like an arrow into the 
cavity where bound TCAs were crystallized with the transporter, near the extracellular 
gate, see figure 5.2.
On the intracellular face there are two noticeable loops forming α helices. IL1, formed to a 
short  α helix  connects  TM2 and TM3 and participates  on the substrate  translocation 
pathway by occluding the intracellular gate. The second short  α helix is IL5 connects 
TM10 and TM11.
Figure 5.3: LeuT depicted in 2D. The structural repeat of the first ten domains is marked as 
pink and blue arrows.
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Figure 5.4c: Interaction partners of Na1 in the 
binding site of LeuT
Figure 5.4a: Interaction partners of Leucine in 
the binding Site of the LeuT
Figure 5.4d: Interaction partners of Na2 in the 
binding site of LeuT
Figure 5.4b: Van-der-Waals surface of the 
binding pocket. Red lipophilic, blue 
hydrophilic
ligand residues domain ligand residues domain
leucine A22(BB) TM1 Na(1) leucine -
-NH3+ F253(BB) TM6 A22(BB) TM1
T254(BB) TM6 N27(BB,SC) TM1
S256(SC) TM6 T254(SC) TM6
leucine Na1 - N286(SC) TM7
-COO- L25(BB) TM1
G26(BB) TM1 Na(2) G20 TM1
Y108(SC) TM3 V23 TM1
leucine V104 TM3 A351 TM8
-CH2-CH-(CH3)2 Y108 TM3 T354 TM8
F253 TM6 S355 TM8
S256 TM6
F259 TM6
S355 TM8
I359 TM8
Table 5.2 Residues interacting with 
sodium and moieties of leucine, BB = 
back bone, SC = side chain
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The binding site of leucine in the crystal contains the substrate and two sodium ions. It is 
totally free of water. The charged moiety of leucine is coordinated by hydrophilic residues 
and  one  sodium.  The  lipophilic  part  of  leucine  protrudes  in  a  lipophilic  pocket, 
sourrounded by aliphatic and aromatic residues. Figures 5.4 a - d show the binding sites 
of leucine and the sodium ions. In table 5.2 the involved residues are listed.
In the first 10 TMDs, there is a structural repeat from TM1 to TM5 and from TM6 to TM10 
(see figure 5.3). The alpha carbons of the first 5 TMDs can be superposed over the next 5 
TMDs. The involved domains in the substrate permeation are TM1, TM3, TM6 and TM8, 
the protein core. The highest degree of conserved residues was found in TM1 and TM6, 
both part of the substrate and ion binding site in common with TM3 and TM8. In the 
centre of these four TMDs, in the half  way through the phospholipid bilayer,  distinct 
unwound regions are forming the binding site for leucine and two sodium ions. TM2, 
TM4, TM5, TM7, TM9 and TM10 support the protein core in conformational changes and 
anchoring in the membrane. in TM9 and TM12 are involved in multimerization, as the 
LeuT was crystallised as dimer.
The extracellular gate consists of R30 and D404, which can form a salt bridge, and Y108 
and F253, which allow access to the extracellular solution for the binding pocket. For 
substrate entering the gate must be opened. After entering of Na1, leucine and Na2, 
conformational changes occur and the gate closes. Further movements of TM1 and TM6 
opens the intracellular  gate consisting of  R5 and D369,  forming a salt  bridge in the 
closed conformation. Substrate and ions are released and the transporter returns to the 
outward  faced  conformation  for  the  next  cycle.  The  stoichiometry  for  LeuT  is 
sodium:chloride:substrate  =  2:0:1.  In  contrast  to  the  mammalian  monoamine 
transporters, LeuT is chloride independent (Yamashita et al., 2005, Singh et al., 2007, 
Zhou et al., 2007).
Figures 5.5a - c: show the gates of LeuT: (a) intracellular view: R5 and D369 marked in green
(b) side view: location (green circles), (c) from extracellular: R30 and D404 also marked in green.
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5.2 Neurotransmittertransporters
During the neuronal transmission, neurotransmitter are released into the synaptic cleft to 
forward  impulses  from  one  neuron  to  the  next  one.  It  is  important  to  remove  the 
transmitter rapidly from the synaptic cleft to terminate signalling. This mechanism was 
first elucidated by G. Hertting and J. Axelrod in 1961. The transporter are located at the 
presynaptic membrane of the transmitter emitting neuron in the peri-synaptic region out 
of the synaptic cleft (Torres et al., 2003)
The mammalian NSSs are coded on the SLC6 gene. This gene consists of transporters for 
neurotransmitters and solutes, that carry selectively their respective substrate with the 
sodium gradient  through the cell  membrane. The degree of sequence identity in this 
group is between 40 % and 90 %. In Table 5.3 the members of the SLC6 gene are listed:
gene substrate localisation
SLC6A1 P50531 GAT1 brain
SLC6A2 P23975 NET norepinephrine transporter brain, lung
SLC6A3 Q01959 DAT dopamine transporter brain
SLC6A4 P31645 SERT serotonin transporter brain, platelets, placenta
SLC6A5 Q9Y345 GlyT2 glycine transporter spinal cord
SLC6A6 P31641 thyroid, placenta, retina
SLC6A7 Q99884 PROT
SLC6A8 P48029 CT1 kidney, brain, eye, testis, muscle
SLC6A9 P48067 GlyT1 glycine transporter brain
SLC6A10
SLC6A11 P48066 GAT4
SLC6A12 P48065
SLC6A13 Q9NSD5 GAT2 liver
SLC6A14 Q9UN76 ATB0+ amino acid transporter mammary gland
SLC6A15 Q9H2J7 NTT73 orphan Na/Cl dependent NSS cerebellum, placenta
SLC6A16 Q9GZN6 NTT5 orphan Na/Cl dependent NSS testis, epithelium
SLC6A17 Q9H1V8 NTT4 orphan Na/Cl dependent NSS
SLC6A18 Q96N87 XTRP2 Na/Cl dependent transporter kidney, colon
SLC6A19 Q695T7 B(0)AT1 neutral amino acid transporter kidney, colon
SLC6A20 Q9NP91 SIT1
swissprot 
code abbrev.
gamma-aminobutyric acid transporter
TauT taurine transporter
proline transporter hippocampus, colon
creatine transporter
gamma-aminobutyric acid transporter fetal brain
Betaine/GABA transporter corpus striatum, kidney
gamma-aminobutyric acid transporter
proline transporter
Table 5.3: Members of SLC6 gene family, taken from www.expasy.org
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5.2.1 Structure and Function
As  mentioned  above,  the  bacterial  homologue  of  the  mammalian  NSS,  LeuT,  gives 
insights  in  their  three  dimensional  structure.  Hydropathy  analysis  reveal,  that  the 
transporters  are  organised  to  12  TMDs  with  intracellular  N-  and  C-termini.  Previous 
studies that TM1, TM3, TM6 and TM8 participate in substrate translocation. The main 
differences between the bacterial and the mammalian transporters are located in EL2, 
that  is  about  25  amino  acids  longer  and contains  glycosylation  sites  and disulphide 
bonding domains, the of course different binding site and the chloride dependency of the 
SERT  and  DAT  (Yamashita  et  al,  2005,  Beuming  et  al.,  2006).  The  glycosylation  is 
necessary for transporter trafficking and function. Also the NH3+ and COO- termini are 
longer.  LeuT forms dimeres in the crystal,  so it  is suppsed,  that  also SERT and DAT 
appear as dimers and tetramers (Chen et al., 2000; Rudnick, 2007).
The sequence identity of LeuT to SERT and DAT is at 21 and 20 %, respecitvely. It is a 
rather low, but the homology ranges from 40 % to 45 %. In the binding site, the amount 
of identical residues is about 50 % (Zhou et al., 2007, Beuming et al., 2007, Ravna et al, 
2007). SERT and DAT share about 50 % of sequence identity (Rudnick et al., 1998; Chen 
et al., 2000).
5.2.2 The Serotonin Transporter, SERT
The primary sequence of the human SERT consists of 630 amino acids with a formula 
molecular weight of about 70.3 kDa (www.expasy.org). It is expressed across the plasma 
membrane of neurons and glia, and also on platelets and transports the proper substrate 
with  high  selectivity.  The  SERT is  also  targeted by other  substrates,  e.g.  MDMA and 
indoles, and inhibitors, e.g. Cocaine.
Most of the corresponding residues in the binding site of SERT are identical to those in 
LeuT. A substantial difference is D98, where on this position in LeuT is G24. Serotonin 
does not have a carboxyl group, so that the acidic moiety of D98 coordinates with the 
amino group of 5HT. Mutations on this aspartatic acid leads to a loss of transporter 
function (Henry et al., 2003). Only five out of twelve residues interacting with leucine in 
the LeuT structure are mutated in the binding site of SERT. Three of them are changed to 
smaller residues in the hydrophobic part of the binding site, that is rooted to the bigger 
indole moiety of serotonin (Rudnick, 2007).
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Because of the stoichiometry of transport action of SERT (see figure 5.6), it is supposed 
that only one Na+ is bound and co-transported with 5HT. The analysis of the conserved 
residues around the two Na+ in LeuT suggest, that also in SERT could be bound a second 
Na+, that is not transported (Rudnick, 2007). Recent investigations on the Cl- binding site 
in NSS members exhibited a binding site for Cl- in NSS. The Cl--coordinating residues, 
serines, threonines and tyrosines, are conserved over the chloride dependent mammalian 
NSS but not in the Cl- independent bacterial members LeuT, TnaT and Tyt1, where these 
resdues are glutamates and aspartates. Mutations of LeuT (E290S) led to a Cl- dependent 
transporter and analogue mutations in SERT (N368D) led to a Cl independent transporter. 
(Forrest et al., 2007; Zomot et al., 2007)
SERT co-transports its substrate 5HT with Na+ and Cl- through the membrane into the 
cytoplasm and aniports  one  K+ to  the  extracellular  side  in  a  neutral  electrochemical 
manner.  For  transportation  it  undergoes  a  series  conformational  changes.  The 
permeation pathway is located in TM1, TM3, TM6 and TM8 (Chen and Rudnick, 2000). 
The order of the binding steps is not evident. In the outward faced conformation, the first 
ion  binds,  that  is  supposed  to  fix  the  transporter  in  open  state.  After  substrate 
recognition 5HT enters the binding site. The second ion causes a conformational change 
to the occluded state. A next conformational change opens the intracellular gate and 
releases the solutes. Unique for the NSS is the following step, where K+ binds from the 
cytoplasmatic side and leads the transporter to the outward faced state to release it on 
the outside of the cell. The outward faced position is the preferred for SERT (Rudnick, 
2007).
Figure 5.6: transport 
action of SERT and 
stoichiometry from 
Rudnick, 2007. The 
stoichiometry of the 
transport is 
5HT+:Na+:Cl-=1:1:1 
inward and K+=1 
outward. The net 
charge transport is 0, 
in contrast to the 
other members of 
the NSS.
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5.2.3 The Dopamine Transporter, DAT
DAT in its primary sequence is a little smaller than SERT and consists of 620 amino acids 
with  a  molecular  weight  of  68,5  kDa  based  on  the  primary  amino  acid  sequence 
(www.expasy.org). Located on the terminals of dopaminergic neurons, it transports the 
substrate  dopamine  and  also  norepinephrine.  Among  others  the  DAT  is  targeted  by 
cocaine and MPD as inhibitor and substrates like amphetamines and the neurotoxin MPP+ 
(Torres et al., 2003).
The sequence identity to LeuT is a little lower, than the sequence identity from SERT to 
LeuT  (see  table  6.4).  Crucial  for  substrate  binding  and  translocation  is  D79,  that 
coordinates the amine group from dopamine and the Na+. This residue corresponds to 
LeuT G24 and SERT D98. Mutations on this position lead to loss of function. Also in DAT, 
the  region  of  the  highest  density  of  conserved  residues  is  found  in  the  domains 
participating in substrate translocation. As also the SERT, five out of twelve residues are 
mutated in the binding site of DAT. And similarly four of them are changed to smaller 
residues, due to the larger moiety of dopamine in the hydrophobic part of the binding 
pocket, depicted in table 6.5 (Chen and Reith, 2000).
The  transport  stoichiometry  of  DAT  is  distinct  to  LeuT,  because  only  one  Na+ is 
transported and also distinct to SERT, because there is no antiport of K+. Dopamine is co-
transported with Na+ and Cl-. The sodium gradient is the driving force for the transport 
action.  In  contrast  to  SERT,  the  transport  action  is  not  electrochemical  neutral: 
dopamine+:Na+:Cl- =  1:1:1,  so  one  positive  charge  is  transported  into  the  cell.  The 
mechanism  of  substrate  translocation  is  supposed  to  be  similar  in  NSS  family.  As 
mentioned above,  Na+ enters the transporter for  keeping the extracellular  gate open. 
After entering of dopamine and chloride, conformational changes occur and close the 
gate  between  D79  and  Y176.  When  these  residues  interact,  further  conformational 
changes lead to an opening of the intracellular gate and release of substrate and ions 
(Torres et al., 2003; Chen and Reith, 2000)
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 6 Materials and Methods
As previously mentioned, the NSS terminate neuronal transmission by reuptake in the 
presynaptic neuron. They are also a target for CNS-modulating drugs like SSRIs and TCAs 
and as well for abused drugs as amphetamines and cocaine. The mode of action can be 
distinguished  between  substrate  (5HT),  inhibitor  (SSRI)  and  substrate  type  releaser 
(MDMA). Due to the lack of a crystal structure of the NSS, we built homology models of 
SERT, DAT and NET for running docking simulations. In this work we investigated the 
protein ligand interactions and the binding modes of the substrates and inhibitors of the 
SERT and the DAT. For all simulations we used the software package Molecular Operating 
Environment, Version 2007.09.
 6.1 Molecular Operating Environment
The  Molecular  Operating  Environment  (MOE),  developed  by  the  Chemical  Computing 
Group (CCG),  Canada (www.chemcomp.com) is a software package of applications for 
drug  discovery,  used  by  academic  and  industrial  researchers.  This  package  contains 
multiple features with a graphical user interface:
• Cheminformatics and QSAR: descriptors, similarity search, high throughput search, 
QSAR-predictive models
• Pharmacophore discovery: pharmacophore search, conformation analysis
• Molecular modelling and simulations: molecule builder, data transfer, molecular 
dynamics and mechanics
• Protein  modelling  and  bioinformatics:  alignment,  fold  and  rotamer  libraries, 
mutations
• Structure-based design: site detection, surface imaging, docking, protein-ligand-
interaction-fingerprint 
• Methods development and deployment: scientific vector language (SVL)
(www.chemcomp.com)
In the present study we used the protein homology modelling and molecular modelling 
and simulation features, i.e. docking, which will be described in the following.
49
 6.2 Homology Modelling
We started the procedure of creating homology models by using the crystal structure of 
LeuT as template and the comprehensive alignment published in by Beuming et al., 2006 
(http://icb.med.cornell.edu/trac).  The methodology of homology modelling with MOE is 
that conserved residues are copied identically over the coordinates of the template. For 
the differing residues the backbone coordinates are used to place the side chains, based 
on the rotamer library. For the calculations the Amber99 forcefield was used.
Figures 6.1a - c are shown in side view
Figure  6.2a-c:  The  pictures  show our  template  LeuT  in  the  same  manner  as  above,  but  the 
transporter rotated 90°. This is the view from the extracellular space (top view).
Figure 6.1a: This picture shows 
our template with bound leucine 
in the centre of the protein.
Figure 6.1b: The binding site is 
depicted as surface.
Figure 6.1c: Both the binding 
site and the external vestibule 
are displayed as surface.
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The precondition of an accurate homology model is a reliable template. Very important 
criteria for the template are e.g. sequence identity, homology, functional similarity and 
the  resolution  of  the  X-ray  structure.  The  crystal  of  the  LeuT  was  published  with  a 
medium resolution of 1.65 Å. It shows the transporter with bound leucine in the substrate 
occluded state, two Na+ ions in the binding site and one Cl- ion on the extracellular part 
of the protein. The sequence identity of about 20 % between LeuT and the monoamine 
transporters is very low (Yamashita et al., 2005).
We started MOE homology modelling with aligning the sequences of the template and the 
sequences of SERT, DAT and NET manually in the sequence editor of MOE, according to 
Beuming et al., 2006. The sequences of human DAT, NET and SERT were obtained from 
the swiss-prot database as fasta-file (www.expasy.org).
Figure 6.3: Ramachandran Plot of LeuT; the green areas depict the protein core 
regions and the red areas show allowed regions concerning the Φ and Ψ angles. 
Glycine and proline have divers allowed regions because of their different 
structure.
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Figure 6.4: Alignment  of the template with the sequences of DAT, NET and SERT is based on 
Beuming et al., 2006. Colour code: yellow = identical residues; orange = identical amino acids in 
DAT, NET and SERT; red lines = transmembrane helices, blue lines = loops, yellow lines = beta 
sheets.
After removing water, b-octoglucoside and the Na+ and Cl- ions from the crystal structure, 
we  started  the  homology  modelling.  The  software  calculated  the  models  by  using  a 
Boltzmann-weighted  randomized  modelling  procedure  and  databases  for  sidechain 
orientation and loop folding. Scoring and refinement was based on electrostatic solvation 
energy,  calculated  with  generalized  Born/Volume  Integral  (GB/VI)  methodology.  The 
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duration of the modelling procedure was approximately 6 hours on a Intel Pentium Core 
2 Duo with 2.2 GHz and 2 GB RAM.
 6.2.1 The Model of the Serotonin Transporter
During the creation of the models, MOE generated ten intermediates. The final model is 
based on the best scored intermediate of GB/VI. Both termini have been removed from 
the sequence. As depicted in table 6.1, only few outliers have been reported.
Table  6.2:  Involved  domains  where  the  residues 
have  been  reported  as  outliers.  The  colour  code 
refers to Figure 6.5
Figure 6.5: The protein backbone is shown as line 
for  visualising  the  location  of  the  outliers.  In  the 
centre the binding site is depicted as surface.
Domain Residue Outlier Colour
TM3 I167 Rotamer yellow
EL2 G244 Ramachandran plot green
EL4 M386 Ramachandran plot green
EL4 A401 Ramachandran plot green
IL4 P455 Ramachandran plot green
TM11 S559 Ramachandran plot green
Table 6.1: Parameters of the final model and the intermediates. This table shows calculated energetic 
values and putative outliers in back bone (BB) bond lengths, BB angles, BB torsions and rotamers. As 
well it shows atom clashes, which are absent in the final model.
name GB/VI E sol E ele E vdw
Model #1 -15654,03 -1270,16 -1428,86 -1977,50 28 1 19 20 3
Model #2 -15665,99 -1275,49 -1426,12 -1912,11 29 2 27 27 1
Model #3 -15654,58 -1163,05 -1459,46 -2030,58 18 0 18 21 4
Model #4 -15630,86 -1308,58 -1411,74 -1927,39 24 1 15 28 3
Model #5 -15635,80 -1297,02 -1409,80 -1983,55 25 0 18 33 5
Model #6 -15662,34 -1152,38 -1442,01 -1947,21 23 0 18 26 4
Model #7 -15634,03 -1292,02 -1399,94 -1981,78 24 1 21 17 4
Model #8 -15612,79 -1193,59 -1444,77 -1971,49 22 1 20 28 6
Model #9 -15639,60 -1260,46 -1371,41 -2063,76 19 1 15 25 2
Model #10 -15607,00 -1230,59 -1413,81 -2012,52 26 1 21 21 5
Final model -15516,69 -840,41 -1338,23 -2734,49 0 0 2 6 1
Atom 
Clashes
BB Bond 
Outliers
BB 
Angle 
Outliers
BB 
Torsion 
Outliers
Rotamer 
Outliers
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We evaluated our model first by inspecting the binding site. The TMDs involved in the 
cavity show a sequence identity of  more than 40 % between the LeuT and the SERT 
accordingly the DAT, see table 6.5. This suggests a highly conserved structural feature of 
the  NSS  for  substrate  translocation  (Yamashita  et  al,  2005;  Zhou  et  al,  2007).  The 
corresponding residues which are directly interacting with leucine we account as binding 
site in SERT since there is a high degree of identity. In our model, we also found the same 
residues within a radius of 4.5 Å from the centre of the cavity by using the site finder.
Also the chloride and the sodium binding sites are well defined (Forrest et al., Zomot et 
al). The extracellular gate formed by the residues R104 and E493 as well as Y176 and 
D98 which induces the translocation are in proximity (Rudnick, 2007). We further looked 
for engineered Zn and Cd binding sites, which confirm the findings on sterical proximity 
(Henry et al., 2006; White et al., 2006; Mitchell et al., 2004). Since our major focus was on 
the binding site, we did not consider the disulphide bond in EL2. It is supposed due to 
the fact that C200 and C209 are not accessible with MTS reagents (Kamdar et al., 2001).
Figures 6.6 a, b show the binding site of SERT. The residues within a radius of 3 Å from the centre 
are depicted. left = side view; right = top view.
Figure 6.7 a, b: The binding site is depicted as surface: red = lipophilic cavity, blue = hydrophilic 
interactions, white = H-bond contacts; left = side view; right = top view. Concerning the labelling, 
the following figures from the binding site have been taken from the same perspective.
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The Ramachandran plot reports 5 outliers concerning the two angles Φ and Ψ. None of 
them is located near the binding site. Our model contains 529 amino acids due to the 
eliminated N and C terminus. Five residues are located outside of the allowed regions in 
the  Φ-Ψ-plot. The amount of outliers is lower than 2 %, which assigns a further quality 
criterion of our model.
 6.2.2 The Model of the Dopamine Transporter
As  well  as  the  final  model  of  the  SERT  also  the  model  of  DAT  shows  few  outliers 
concerning the rotamers, torsions and angles. Here again no atom clashes are reported. 
Both termini have again been removed from the sequence for modelling.
Figure 6.8: The Ramachandran Plot of the SERT. The residues, which are 
marked in blue are located in not  allowed regions due to their  angles. 
None of them is in proximity of the binding site. These uncertainties occur 
in change-overs of the secondary structure, e.g. from helix to loop.
55
The validation of the model correlates to those in SERT. For this transporter we primarily 
focused on the binding site to identify differences in the binding mode of MPD between 
DAT and SERT. Both Na+ binding sites and the Cl- binding site, which are located near the 
substrate binding site, are similarly well detectable in DAT.
Figure 6.9: Ramachandran Plot  of DAT. This model contains 531 amino acids 
because we left out both termini for modelling. As well as in SERT five residues in 
DAT are located outside of the allowed regions, also marked in blue. The amount 
of outliers is again in DAT lower than 1 % which denotes a good model.
Table 6.3: Parameters of the final model and the intermediates (BB = back bone). As table 8.1, it 
shows calculated energetic values and putative outliers in the mentioned categories. Also the model 
of the DAT sows good parameters.
name GB/VI E sol
Model #1 -14833,06 -1285,35 -1289,16 -2132,15 17 2 14 21 5
Model #2 -14835,38 -1314,88 -1281,15 -2230,52 14 0 16 24 3
Model #3 -14808,46 -1072,73 -1284,67 -2109,99 14 0 9 24 4
Model #4 -14814,07 -1273,75 -1285,3 -2177,41 13 0 14 28 4
Model #5 -14830,31 -1265,66 -1273,85 -2142,26 14 1 13 23 2
Model #6 -14811,53 -1141,37 -1296,34 -2147,61 21 0 21 29 2
Model #7 -14778,66 -1268,79 -1262,96 -2154,22 18 2 13 26 2
Model #8 -14814,91 -1161,11 -1282,55 -2083,73 22 0 12 25 5
Model #9 -14793,96 -1217,63 -1240,55 -2142,9 17 1 18 24 4
Model #10 -14820,6 -1161,4 -1285,8 -2116,04 17 0 18 22 3
Final model -14665,65 -853,33 -1202,81 -2775,02 0 0 2 9 4
E ele E vdw
Atom 
Clashes
BB Bond 
Outliers
BB 
Angle 
Outliers
BB 
Torsion 
Outliers
Rotamer 
Outliers
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Following our aim to elucidate the binding modes of substrates and inhibitors in SERT 
and to explain the differences in the binding mode of MPD in DAT and in SERT, we left 
out the evaluation of the homology model of NET. A short view on the binding site shows 
similar orientations of the residues in this region of NET, which suggests also a reliable 
model.
 6.2.3 Comparison of the Models
Table  6.4:  The  deviations  between  the  template 
LeuT  and  the  models,  measured  over  the  whole 
structure. Due to a sequence identity of about 20 % 
between the template and the model, an RMSD of lower than 1.5 Å over the whole structure is very 
well. The increasing deviation between the three models is due to the differences in the modelled 
loops but mainly due to EL2 (blue circles in Fig 6.10b)
RMSD LeuT DAT NET SERT
LeuT 1,2621 1,3812 1,2699
DAT 1,2621 3,4352 2,5364
NET 1,3812 3,4352 3,9220
SERT 1,2699 2,5364 3,9220
Figure 6.10a: Overlay of the models of SERT, 
DAT and NET. The backbone is depicted as line. 
The residues which are outliers are displayed in 
spacefill mode. None of them is in proximity of 
the binding site. They rather are located at 
structural changeovers, e.g. loop-helix. Colour 
code: SERT = pink, DAT = green, NET = blue.
Figure 6.10b: Overlay of the template LeuT with 
the three models depicted in tube mode. This 
picture shows the differences due to the loop 
modelling which effects large RMSD over the 
whole proteins (see table 6.4).
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 6.3 Molecular Modelling and Simulation
The  main  part  of  the  present  study  was  running  docking  of  selected  ligands  in  the 
putative binding site of the homology models. Hereafter we describe the procedure of 
docking into the models of SERT and DAT and ranking the obtained docking poses. Based 
on the crystal structure of LeuT, we elaborated a method to reduce the amount of poses 
after redocking for ending up in the pose of leucine near the crystal structure of LeuT. We 
considered geometric and energetic parameters for this pose shrinking procedure.
Important parameters and program features for docking and ranking are
• Merck forcefield: In contrast to Amber or Charmm, this forcefield is parameterised 
for small organic ligands. We used this forcefield during the docking run, because 
the protein was held rigid.
• Dielectric constant: This parameter was set to 4 for the interior of the protein and 
to 80 for the exterior medium. A dielectric constant of 1 matches vacuum, 2 - 8 are 
used for protein medium and 80 equals water (Ermondi et al., 2006).
• Protein Ligand Interaction Fingerprint (PLIF): This tool 
is  a  method  for  summarising  interactions  between 
the ligand and the protein in a fingerprint scheme. 
The interactions of the residues with the ligand, such 
as hydrogen bonding or ionic interactions are divided 
in single bits
• Placement:  Alpha  triangle  places  the  molecule  by 
superposing ligand atom triplets and triplet points in 
the binding site, which are alpha sphere centers. For 
the determination of the pose a random triplet of the 
alpha  sphere  and  a  random  triplet  of  the  ligand 
atoms with a random conformation are used.
• Scoring: We used London ΔG as scoring function. It estimates the free energy of 
binding between the pose and the protein.
• Refinement: It  is an energy minimisation step during the docking run. Only the 
ligand is considered while the protein is held rigid.
Figure 6.11: Splitting of the 
interactions between the 
residue and the ligand in the 
PLIF
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 6.3.1 Ligand Preparation
The  first  step  before  docking  was  creating  the  ligands  with  the  molecule  builder 
integrated in MOE. After energy minimisation a conformational database was generated 
by molecular dynamic simulation. In this simulation the molecules are heated up to 2000 
°K for 50 ps in the Merck forcefield (MMFF94x) and under vacuum conditions (dielectric 
constant  =  1).  The  resulting  conformers  have  been written in  a  database  which  was 
energy minimised. We selected the 200 most  different conformations on basis of the 
potential energy of the ligand and the RMSD to the conformation with the lowest potential 
energy (Ermondi  et  al.,  2004).  For  redocking of  leucine  into the  crystal  structure  we 
extracted the ligand from the .pdb-file  2A65 an created the conformer database in a 
similar way.
Figure 6.12: On the structure of leucine extracted from the crystal structure (left) the MD 
simulation was applied, which resulted in 200 conformations. The overlay of all these structures is 
represented on the right side.
 6.3.2 Defining the Binding Site
For the homology models,  we defined the binding site by using the built  site finder, 
implemented in MOE. It calculates possible active regions in a protein considering the 
three dimensional coordinates based on alpha shapes. The algorithm also distinguishes 
between hydrophilic and lipophilic regions in the pocket (see figure 6.14). Each residue 
within a radius of 6 Å has been part of the binding site during the docking run. These 
residues are the corresponding amino acids in the binding site of LeuT, see figure 6.14 
(Yamashita et al., 2005; Rudnick, 2007; Beuming et al., 2006; Huang et al. 2007). For 
redocking the binding site was defined by using the bound ligand.  Only  the directly 
interacting residues within a radius of 3 Å have been considered.
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Figure 6.13: This picture shows the residues, which surround the binding site in the template as 
well  as  in  the  models.  The  depicted  sequences  are  for  each  the  centre  of  the  named 
transmembrane domains.  Colour  code:  yellow = overall  sequence  identity,  orange = sequence 
identity between the monoamine transporter, light blue = residual amino acids in DAT and the 
identical residues in either the NET or the SERT, red = residue only in NET, green = residue only in 
SERT. Residues important for ligand interactions are marked with a green circle.
Table 6.5: 
Alignment of 
residues lining the 
binding sites. This 
shows a sequence 
identity of about 
47 %.
green=identity of 
all transporters
yellow=two trans-
porters share 
identical residues
red=individual 
residues.
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Figure 6.14: The binding site of LeuT with 
bound leucine (yellow). The dots are the 
dummy atoms: white = lipophilic regions, 
red = hydrophilic centres
Domain LeuT SERT DAT
TM1
N21 Y95 F76
A22 A96 A77
G24 D98 D79
L25 L99 L80
G26 G100 A81
N27 N101 N82
TM3
V104 I172 V152
Y108 Y176 Y156
TM6
F253 F335 F320
T254 S336 S321
L255 L337 L322
S256 G338 G323
F259 F341 F326
TM8
A351 L434 L418
T354 D437 D421
S355 S438 S422
I359 G442 G426
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 6.3.3 Running Docking
We started the docking runs with redocking of leucine in the crystal structure of LeuT for 
evaluating the reliability of our docking program. The settings were adapted to the Merck 
forcefield  (MMFF94x),  an  internal  dielectric  constant  of  4  and  an  external  dielectric 
constant of 80. Since MOE 2007.09 provides an energy minimisation step and two scoring 
functions during the docking run, the processing time is rather high. We ended up in a 
duration between 6 and 8 hours per ligand on an AMD Athlon X2 with 2.2 GHz and 2 GB 
of RAM.
The first analysis of the redocking results was measurement of the deviation between the 
best pose and the crystallised leucine by RMSD, see figure 8.15 and tables 8.5 a and b.
Due to the increase in the amount of crystal structures the docking programs are also 
improving and tested in benchmarks.  A threshold of  2 Å RMSD from the crystallised 
ligand is well  accepted. Refering to David et  al.,  2005 the docking algorithm of MOE 
2007.09 performed very well.
Due to the redocking results we elaborated a method to find the pose with the lowest 
deviation by using calculated descriptors. Following we present the description of our 
method for ranking and selecting the poses in SERT and DAT based on the analysis of the 
redocking of leucine into LeuT.
best pose 0.3144 Å
highest deviation 4.6042 Å
Figure  6.15:  The  picture  shows  those  poses, 
with  the  lowest  RMSD  compared  to  the 
template.  In  table  6.6b  the  RMSD  values  are 
shown.
Table 6.6b: Referring to figure 6.15, the deviations 
of the poses after redocking.
colour deviation from template number %
yellow Template, 0 Å 0 0
red 0.3144 < 0.3590 Å 122 6,12
green 0.5525 < 0.6244 Å 141 7,07
blue 0.7061 < 0.8196 Å 142 7,12
sum 405 20,32
Table 6.6a: These tables show the results 
of redocking. Best pose is those with the 
lowest  deviation  from  the  crysallised 
ligand.
poses number %
all 1993 100,00
< 1 Å RMSD 661 33,17
< 1.65 Å RMSD 1007 50,53
< 2 Å RMSD 1298 65,13
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 6.3.4 Ranking the Poses
In the literature, amounts of data are available concerning 
mutagenesis experiments on the SERT and the DAT. In the 
binding  site  few very  important  residues are  crucial  for 
substrate binding and transporter function, see table 8.5. 
Mutation of one of these residues, either ligand binding or 
transporter function or both is reduced. These data reveal 
important interactions between the ligand and the protein. 
The exact binding mode of substrate and inhibitors in the 
DAT and the SERT is still a topic of research. Recent papers 
give  suggestions  on  the  binding  mode  of  serotonin, 
dopamine, cocaine and CFT (Beuming et al., 2008 revealed 
pose of dopamine and CFT in DAT similar to our findings 
in SERT; Celik et al., 2008 published a model of the SERT 
with bound ligand similar to our top ranked poses; Huang 
et al., 2007 revealed the binding mode and interactions of dopamine in DAT; Kaufmann 
et al., 2008 in contrast to Celik et al. and our poses a different orientation of 5HT in the 
binding site is suggested; Xhaard et al., 2008 suggests differing binding modes of the 
ligands in the NSS).
In contrast to the high throughput screening of libraries for hit finding, we used docking 
to elucidate the binding mode of substrates and inhibitors. It is a quite challenging topic 
since small ligand docking is not capable to find one single and correct pose by using 
scoring functions or calculated energetic parameters. As mentioned above the sequence 
identity between the template and the query protein is rather low, docking into such a 
model has an inherent error and more than one solution. After the docking run we 
obtained up to 3000 poses for each ligand. In order to select plausible poses, we 
followed a multi-step procedure, based on geometrical and energetic parameters which 
describe the ligand or the complex. The first step was creating the protein ligand 
interaction fingerprint (PLIF). It provides separation of poses by selecting interactions with 
defined residues. Our first selection criterion was the occurrence of interactions with 
residues in the binding site. The residues with the highest frequency in the PLIF are Y95, 
D98, F335 and S438, which have been identified in other docking studies (Celik et al., 
2008), and shown to be important, based on mutagenesis data (Henry et al, 2003 and 
2006)
Figure 6.16: Procedure of pose 
shrinking
Protein Ligand Interaction Fingerprint
Clustering the RMSD distance matrix
Selection by energetic parameters
Energy minimisation
3000 Poses
600 Poses
2 Clusters
up to 50 Clusters
2 Poses
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Figures  6.17  a  and  b:  The  visualisation  of  the  protein  ligand  interaction  fingerprint  of  the 
redocking results. The ordinate shows the amount of 1993 docked poses. On the abscissa the 
interacting residues are depicted, splitted into interaction bits (see Fig. 6.11). The figure above 
shows the sum of hits per residue. Below, the interaction pattern is dissipated to the single pose.
The selection per PLIF reduced the amount of poses up to 700. For these we built a root 
mean  square  deviation  (RMSD)-distance-matrix  to  consider  the  three  dimensional 
orientations of the poses due to the fact that poses with similar spatial orientation (low 
RMSD) can have strongly deflected energetic  parameters.  We calculated the distances 
between all of them and obtained a n*n matrix, which was our input database for the 
clustering  by  the  statistical  Ward-method.  The  Ward  methodology  is  a  hierarchical 
agglomerative  clustering  method  on  basis  of  the  distances  between  individuals. 
Depending on the dissimilarity of the generated poses, the threshold was set to 10, 20 
and 50 respectively. Each docking pose has been assigned into a cluster of similar poses.
Formula 6.1: Root Mean Square Deviation (RMSD)
RMSD =∑i =1
n
aix−bix
2aiy−biy
2aiz−biz
2
n
a, b: compared atoms
x, y , z: absolute 
coordinate
i: molecule
n: number of 
molecules
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The further criteria were energetic parameter, calculated during and after docking. Based 
on the analysis of redocking, we considered the following descriptors:
• Potential energy of the ligand (E), which characterises only the ligand. The most 
favourable redocking poses have been found with this descriptor (cluster 3, RMSD 
< 0.4 Å).
• Calculated pKi of the complex (dock_pKi), that is an estimated value considering 
both the protein and the ligand. It contains a given degree of uncertainty since we 
docked into a homology model (cluster 4, RMSD < 0.6 Å)
• Docking score (E_ASE2), which considers geometrical purposes.
• and  the  Van-der-Waals  energy  (E_rvdw),  a  three  dimensional  descriptor  which 
considers  the  absolute  geometrical  configuration  as  well  as  the  energy of  the 
complex.
The proceeding was to sort the database by each of the mentioned descriptors. We chose 
those clusters containing the top ranked poses, i.e. the pose with the lowest value, was 
dedicated to further analysis. The amount of docked poses was reduced down to about 
200.
Figure 6.18: Cluster of leucine poses in LeuT; x-axis: number of poses, y-axis: 
degree of dissimilarity; red line: threshold of 10 clusters.
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For the remaining poses we included a minimisation for each protein-ligand-complex by 
molecular mechanics to provide slight side chain movements of the binding site. This 
step we applied only for the docking results of SERT and DAT. Finally we selected two 
descriptors which were generated during the energy minimisation to select  the most 
favourable complex:
• the total interaction energy of the complex (E_interaction_total)
• the Van-der-Waals interaction energy of the complex (E_interaction_vdw)
Figure 6.19b: The two best ranked clusters of 
poses after redocking in LeuT,  see table 6.4. 
Yellow = the original ligand
Table 6.7 shows by which descriptor we chose which cluster and also the 
number of docked poses in the chosen cluster.  The colour  code refers to 
figure 6.19b
descriptor cluster deviation range colour
potential energy 3 122 0,3144 to 0,3590 4 green
dock pKi 4 27 0,5874 to 0,5979 86 turquoise
E_ASE2 3 122 0,3144 to 0,3590 1 green
E_rvdw 3 122 0,3144 to 0,3590 11 green
number 
of poses
best pose 
ranked on
Figure 6.19a: Here the overlay of all poses of 
the redocking are shown
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7 Results and Discussion
Similarly  to  the  analysis  of  the  redocking  results  we  performed  the  analysis  for  the 
selected ligands in the SERT and the DAT. Finally we ended up with two protein ligand 
complexes for each ligand.
7.1 Docking Ligands into the Serotonin Transporter
For the docking runs we selected few ligands, where a multitude of biological data is 
available. As docking into homology models is still very risky, we docked substrates and 
inhibitors regarding to the evidence in the literature. One of our aims was to reveal the 
differences in the binding side respectively differences in the binding mode of MPD.
7.1.1 Serotonin
Serotonin  (5HT)  is  the  proper  substrate  of  the  SERT.  It  binds  with  high  affinity  and 
selectivity due to a rapid removement from the synaptic cleft. Due to the lack of a crystal 
structure  of  the  SERT,  the  exact  binding  mode  is  still  not  clear.  According  to  the 
literature, we found, that the interaction of the dimethylamino sidechain with the D98 is 
crucial for binding as well as for substrate transportation (Barker et al., 1999; Henry et al. 
2003).
Figure 7.1: Histogram of the distribution of the interactions between the residues (abscissa) and 
the number of the docking poses (ordinate).
2725 Poses
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Three  further  residues  have  been  hit  during  the  docking:  Y95,  F335  and  S438. 
Interactions of the substrate 5HT with Y95 in TM1 is supposed to be important (Henry et 
al., 2003 and 2006). Recently published articles on in silico docking suggest a similar 
binding mode (Kaufmann et al., 2008; Xhaard et al., 2008; Celik et al., 2008). We selected 
these four residues in the PLIF-tool as first criterion in the cue of reducing the docking 
poses. After exporting the RMSD-distance-matrix we grouped the poses into 20 clusters.
Figure  7.2:  Clustering:  x-axis  shows  the  number  of  poses,  y-axis  depicts  the  degree  of 
dissimilarity;  red  line  =  threshold  of  20  cluster;  red  circles:  the  cluster  we  chose  for  further 
evaluation.
Figure 7.3 depicts the overlay of all poses 
contained in each cluster. The colour code is 
written in Table 7.1.
The 20 clusters we sorted first by potential energy of the ligand, second by Van-der-Waals 
interaction  energy,  third  by  E_ASE2  and  dock_pKi.  Next  we  performed  an  energy 
minimisation step of the protein-ligand-complex by molecular mechanic simulations. It 
allows slight side chain rotations and provides an adaptation of the protein to the ligand. 
Based on the resulting energetic parameters we selected two complexes with the lowest 
Van-der-Waals interaction energy and lowest total interaction energy.
226 Poses
718 Poses
Table 7.1 shows the number of 
docking poses in the respective 
cluster. We chose the cluster with the 
top ranked pose refering to the 
descriptor.
colour cluster descriptor number
red 1 E 54
green 2 86
blue 3 E_ASE2 61
yellow 6 25
E_rvdw
dock_pKi
67
A recently published paper shows a model of the SERT with bound 5HT. The comparison 
of the models shows a similar orientation of 5HT in the binding site (Celik et al., 2008). 
The overall  RMSD of the compared transporter is more than 5 Å which is due to the 
different  orientation of  the large extracellular  loop.  Considering the binding site,  the 
RMSD is lower than 1 Å.
Figures 7.5 a and b: These pictures show the residues which are directly lining the binding cavity 
and in the center the ligand serotonin. It is a direct comparison of the model from Celik et al. and 
our two most favoured poses. Concerning the protein, the orientation of the residues is quite 
similar. The bound ligand differs markably from our selected poses. Yellow = the model of SERT 
with bound ligand from Celik et al., green = minimised pose selected by total interaction energy, 
blue = minimised pose selected by Van-der-Waals interaction energy. The backbone is depicted as 
line.
Figure 7.4a shows the two finally 
chosen poses. Since their 
orientation is very similar, the 
interaction pattern differs, see 
figures; green = total interaction 
energy, blue = Van-der-Waals 
interaction energy
Figure 7.4b: Interaction 
pattern of serotonin selected 
by the total interaction 
energy. The ionic interaction 
between the nitrogen and 
D98 is visible.
Figure 7.4c: Interaction 
pattern of the final pose 
selected by Van-der-Waals 
interaction energy. Since 
the important interaction is 
not present, we favour the 
pose depicted in figure 9.4b
2 Poses
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7.1.2 Methylphenidate
The affinity of MPD to SERT is much lower than to DAT. To elucidate the reason of this 
difference is one of the aims of the present study. Both enantiomers have been docked. 
Due to the flexibility of the ligand 3568 poses for R,R-MPD and 3620 poses for S,S-MPD 
were generated. For the PLIF we selected interactions wit Y95 and D98 in TM1 and S438 
in TM8. The interaction pattern from both enantiomers are quite similar. Compared to the 
interaction pattern of MPD in DAT, there are no significant differences. In SERT there are 
interactions with more residues detected.
Figure 7.6 a and b: Interaction pattern of R,R-MPD and S,S-MPD in SERT obtained by the PLIF
Figure 7.7 a and b: Interaction pattern of R,R-MPD and S,S-MPD in SERT obtained by the PLIF. The 
comparison of 7.6 and 7.7 reveals similar interactions of both enantiomers in both transporters
1143 poses for R,R-MPD and 1174 for S,S-MPD have been clustered into 50 groups from 
which we selected the four top ranked clusters for the energy minimisation. The selection 
of the four cluster for each enantiomer reduced the amount of poses to 107 and 145 
respectively.
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Figures 7.8 a, b and c show again (a) the orientation of our selected poses for R,R-MPD in the 
binding site of SERT and the interaction patterns of our top ranked poses due to (b) the total 
interaction energy (green) and (c) the Van-der-Waals interaction energy (blue). Since the differing 
orientations of the two poses, both show the interaction with D98.
Figures 7.9 a, b and c show a similar orientation and interaction pattern for S,S-MPD. Notably for 
this enantiomer both top ranked poses are orientated similarly.
After energy minimisation the resulting poses show a characteristic difference concerning 
the orientation of the methyl ester group. The ester group of the R,R-enantiomer on the 
one hand points towards the extracellular (Y176 and D98) gate and on the other hand 
towards the hydrophobic part of the binding site (I172, F320 and V343). In contrast, the 
finally  selected poses of  the S,S-enantiomer  show ester  group orientated towards the 
extracellular gate. It suggests that the hydrophobic part of the binding site is occupied by 
the aromatic ring heterocyclic ring.
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7.1.3 Cocaine and CFT
The affinity of Cocaine to SERT and DAT is on an equal level (Torres, 2003). CFT is used 
for experiments as cocaine analogue due to the similar pharmacological properties and 
the  higher  chemical  stability.  The  PLIF  shows  a  similar  interaction  pattern  for  both 
inhibitors of the transporter.
In our docking experiments into SERT, cocaine shows two different poses similar to R,R-
MPD. The orientation of the methyl ester is again different: on the one hand the ester 
group points towards the extracellular gate (Y176 and D98) and on the other hand the 
same moiety is orientated towards the hydrophobic pocket. In contrast, the analysis of 
the docking results of CFT revealed only one pose (see figure 7.13 a)
As depicted in the ligand interaction graphics (see figure 7.12 b and c), the pose selected 
by the Van-der-Waals interaction energy shows the important ionic interaction between 
D98 and the charged nitrogen. This suggests that this pose is more favourable also due 
to the fact, that the ester moiety points towards the extracellular gate (D98 and Y176).
After evaluation of the poses of CFT, we found only one pose. And this pose corresponds 
with  docked  cocaine,  which  was  selected  by  the  Van-der-Waals  interaction  energy.  A 
recently published paper found a similar pose in DAT. Our finding as well as the results 
of  Beuming  et  al.,  2008  favours  this  pose  as  binding  mode  of  tropane  alkaloids.  It 
suggests also, that the binding mode of CFT and cocaine is similar in both the DAT and 
the SERT.
Figures 7.11a Interaction pattern of cocaine 
with SERT, obtained from the PLIF
Figure 7.11b: Interaction pattern of CFT with 
SERT, obtained from the PLIF
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Figures 7.12 a, b and c: As we found in the top ranked poses of R,R-MPD, also for cocaine two 
different ligand orientations have been selected. The pose selected by Van-der-Waals interaction 
energy (blue) shows the interaction with D98 (c). For this reason and as well due to the orientation 
of the ester moiety in the other pose we suggest this pose as fovourable.
Figure 7.13a: We obtained only one single 
pose  for  CFT.  The  aromatic  ring  is 
orientated towards the hydrophobic cavity 
and the ester is in proximity of D98 and 
Y176.
Figure  7.13b:  Interaction  pattern  and  sur-
rounding residues of CFT in the binding site of 
SERT.
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7.1.4 MDMA
This widely abused amphetamine has a higher affinity to SERT than to DAT or NET. We 
obtained  for  each  enantiomer  two  poses.  The  orientation  of  all  four  poses  is  quite 
similare. In comparison to the indoles, we suggest a similar orientation of the scaffold 
between them.
Figure 7.14 a and b show the orientation of our top ranked poses. green = selected by total inter-
action energy; blue = selected by Van-der-Waals interaction energy
7.1.5 DMT and Psilocin
In order to examine differences in the binding mode of small indole alkaloids, we docked 
also DMT and psilocin. Our results show in principle a similar binding mode. However the 
indole moiety of one pose of DMT shows a different orientation in the hydrophobic cavity. 
Compared to the poses of 5HT, the indole scaffold of the N-methyl-substituted indoles is 
shifted deeper into the pocket. We suggest, that the reason of this shift is due to the two 
methyl groups connected with the nitrogen.
Figures 7.15 a, b and c show (a) the top ranked poses of DMT in SERT, (b) the top ranked poses of 
psilocin and (c) the overlay of 5HT (yellow), DMT (green) and psilocybin (blue)
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7.2 Differences and Similarities
After the procedure of analysing the docking poses, we propose that for the binding of 
the  ligands  the  amino  acid  D98  in  SERT  and  its  homologue  D79  in  DAT  are  very 
important. This fact is according to the protein ligand interaction fingerprints and also 
according to the literature. Each of the ligands contain a charged nitrogen, that is placed 
in  the  surrounding  of  the  mentioned  aspartatic  acid.  This  relatively  strong  ionic 
interaction exhibits a sort of ionic anchor point for the ligand binding. The other side of 
the binding cavity there is surrounded by aliphatic and aromatic residues and built up a 
hydrophobic pocket. Our data suggest that the aromatic moiety of the docked ligands 
binds deep in this pocket.
Our data suggest that the substrates are bound in a similar modality. For each of the 
substrate molecules the orientation of the charged nitrogen is towards the D98 and the 
aromatic  part  of  the  molecules  is  bound near  I172,  F320  in  the  hydrophobic  cavity. 
Unfortunately we were not able to detect exactly definite interactions of the hydroxyl 
moieties of serotonin, psilocin and the methylene dioxy moiety of MDMA with residues 
within the binding site. Due to the proximity of these heteroatoms to S438, we suggest a 
direct interaction.
Figure 7.16a: Overlay of all substrates in SERT. It 
shows a similar binding mode.
Figure 7.16b: Overlay of all substrates in DAT. 
The unfavourable poses are marked in orange. 
But for the other poses, a similar binding mode 
is also visible.
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Concerning the orientation of the inhibitors we found similar binding modes within this 
group. The ester moiety of the compounds points towards Y176 and D98, which form a 
part of the extracellular gate and are important for the substrate translocation cycle. In 
comparison to the recently published article on the cocaine binding site in DAT (Beuming 
et al., 2008) we found analogous interactions with the respective residues in SERT. This 
suggests  that  cocaine  shows  the  same  binding  mode  both  in  DAT  and  SERT. 
Unfortunately our data did not show this binding mode in DAT.
At this point we should mention some limitations of our work:
• The template of our model is in the substrate occluded state. Since there is no 
crystal structure of the DAT, NET and SERT molecular modelling studies will have a 
certain degree of error.
• For this study we used only one software package.
• The co-transported ions have not been part of the model during the modelling and 
docking process.
• During the docking run, the receptor was held rigid.
Figure 7.17b shows all docked inhibitors in 
DAT. We suggest few poses as unfavourable 
(orange).
Figure 7.17a shows the docked inhibitors in 
SERT. The poses, where the ester moiety is 
turned into the bottom of the pocked we 
suggest to be unfavourable (orange circle).
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7.3 Conclusion and Outlook
Based on our data we finally conclude the present study with the suggestion, that the 
group of substrates we selected for docking, i.e. 5HT, tryptamines and MDMA bind in a 
similar mode. The charged nitrogen directly interacts with D98 and the aromatic ring 
system is orientated towards the hydrophobic cavity. Unfortunately we were not able to 
detect a direct interaction of S438 with the heteroatoms of 5HT, psilocin and MDMA. But 
the spatial proximity may suggest an interaction. Since the hydroxyl group of Y95 is not 
orientated into the binding site, we were also not able to detect interactions.
The group of inhibitors, i.e. the tropane alkaloids, we chose for the docking experiments 
also bind in a similar mode. As mentioned above, the nitrogen is as well coordinated by a 
relatively strong ionic interaction with D98. The scaffold of all of the inhibitors show an 
ester moiety.  This lead us propose, that those moieties are the inhibitory factor. The 
orientation of the ester was mainly placed towards the extracellular gate. But it needs 
further investigation on this to identify the exact mode of inhibition.
Comparing both the substrates and the inhibitors, we were able to show the coordination 
of the nitrogen with D98 as anchor point of ligand binding. Both groups bind in a similar 
mode due to their orientation of the charged nitrogen and the hydrophobic moieties of 
the ligands. Accordingly to pharmacological data, we suggest that the binding site of 
serotonin, methylphenidate and cocaine are overlapping.
Regarding the homology model, it will be necessary to create new models by using other 
software  and  considering  the  co-transported  ions  during  the  modelling.  Structural 
improvements  to  include  the  disulfide  bond  in  EL2  must  also  be  considered.  The 
extracellular vestibule beneath the kink in EL must be taken into account for possible 
docking into  the  substrate  recognition  site.  A  recently  published paper  suggests  the 
structural  homology  of  a  bacterial  glucose  transporter  with  LeuT.  The  solute:sodium 
symporter vSGLT from Vibrio parahaemolyticus (pdb-code 3DH4) has been crystallised in 
the inward faced conformation and may be a second template for the NSS (Faham et al., 
2008; Forrest et al., 2008)
The  next  step  will  be  to  run  a  molecular  dynamic  simulation  to  elucidate  domain 
movements  or  the  substrate  translocation  pathway.  A  recent  paper  suggests  the 
importance  of  the  extracellular  vestibule  for  the  transporter  activity  and  substrate 
translocation (Shi et al., 2008).
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Abstract: Molecular Modelling Studies for Analysing Interactions of
Substrates and Inhibitors of the Serotonin Transporter
The serotonin transporter (SERT) is a member of the neurotransmitter:sodium symporter (NSS) 
family, as well as the dopamine transporter (DAT) and norepinephrine transporter (NET). Serotonin 
(5-HT)  is  transported  highly  selective  through  the  presynaptic  membrane.  This  substrate 
translocation is effected by a secondary active transport: symport of two sodium and one chloride 
into the cell and antiport of one potassium ion out of the cell. Widely used CNS-therapeutics, such 
as tricyclic antidepressants (TCA) and selective serotonin reuptake inhibitors (SSRI), as well as illicit 
substances like cocaine and indole alkaloids target the SERT.
The ligands have been divided into two groups due to their mode of action: into substrates and 
inhibitors. For getting more information about the differences in the binding mode between these 
groups, we created a homology model of SERT and DAT based on the crystal structure of the 
Leucine Transporter (LeuT), a bacterial homologue of the NSS, published in 2005. The sequence 
identity between LeuT and SERT is around 20 %, which is rather low for creating homology models. 
In 2006, a comprehensive alignment of NSS was published. This study shows a homology of more 
than 40 % between both transporters.
After successful redocking of leucine in LeuT we docked a selection of ligands. The substrates 5-
HT,  MDMA  and  DMT  and  the  inhibitors  cocaine,  WIN  35,428  (CFT  =  2 -carbomethoxy-3 -(4-β β
fluorophenyl)-tropane) and methylphenidate (MPD) have been docked to examine differences in 
the binding mode. We selected the most accurate poses in a four step procedure. In the first step, 
we used the Protein Ligand Interaction Fingerprint (PLIF), implemented in MOE 2007.09, to select 
those  poses  having  interactions  with  residues  that  have  experimentally  been  shown  to  be 
important for the function of the transporter. In the next step we calculated an RMSD-distance-
matrix  that  was  used  as  input  for  cluster  analysis  to  generate  homologous  groups  of  the 
remaining poses. Next we selected those groups with the most favourable energetic parameters. 
The  last  step  was  an  energy  minimization  of  the  ligand-receptor-complex.  Two  energetic 
descriptors, which describe the interaction energy of the complex were the basis for selecting one 
pose out of the remaining clusters.
Comparing our results to a recently published model of SERT with bound ligand, we found similar 
positioning. The analysis of our best poses showed that the different substrates bind in a similar 
modality. Concerning the inhibitors we found, that the binding mode is also similar within this 
group. In comparison to the recently published article on the cocaine binding site in DAT we found 
analogous interactions with the respective residues in SERT. This suggests that cocaine shows the 
same binding mode both in DAT and SERT. Based on the biological data, we further suggest that 
the binding sites of 5HT, cocaine and MPD are overlapping.
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Zusammenfassung: Bindungsstudie von Substraten und Inhibitoren
in einem Homologiemodell des Serotonin Transporters
Der Serotonin-Transporter (SERT) zählt  gemeinsam mit  dem Dopamin- (DAT) und Noradrenalin- 
(NET)  Transporter  zu  der  Gruppe  der  Neurotransmitter-Transporter  (Neurotransmitter:sodium 
symporter, NSS), einer Gruppe von membranständigen Transportproteinen, die in einem sekundär 
aktiven Transportmechanismus ihr Substrat gegen ein Konzentrationsgefälle in das emittierende 
Neuron transportiert. Serotonin wird gemeinsam mit zwei Natriumionen und einem Chloridion im 
Austausch gegen ein Kaliumion durch die präsynaptische Membran befördert. Der SERT ist auch 
Angriffspunkt für sowohl therapeutisch genutzte Wirkstoffe, wie den trizyklischen Antidepressiva 
oder den selektiven Serotonin Wiederaufnahmehemmern, als auch von psychoaktiven Substanzen, 
wie zum Beispiel Indolalkaloide oder Kokain.
Diese  Liganden  werden  nach  ihrem  Wirkungsmechanismus  in  zwei  Gruppen  eingeteilt:  den 
Substraten  und  den  Inhibitoren.  Um Unterschiede  im  Bindungsmodus  dieser  beiden  Gruppen 
aufzudecken, erstellten wir ein Homologiemodell des Serotonin- und Dopamintransporters (DAT) 
auf  Basis  der  Kristallstruktur  eines  in  Funktion und  Struktur  dem SERT ähnlichen bakteriellen 
Leucin Transporters (LeuT). Die Identität der Primärsequenz von etwa 20 % ist für die Erstellung 
des  Modells  sehr  niedrig.  Eine  im  Jahr  2006  publizierte  Studie  über  die  Angleichung  der 
Primärsequenzen von Neurotransmitter-Transportern ergab eine Homologie der beiden Sequenzen 
von über 40 %.
Wir begannen die Simulationen mit  dem Docken von Leuzin in den LeuT. Danach dockten wir 
verschiedene Liganden des Serotonin Transporters. Als Substrate wählten wir Serotonin, die Indole 
DMT  und  Psilocin  und  das  Amphetamin  MDMA  (Methylendioxymethamphetamin).  Das 
Tropanalkaloid  Kokain  und  sein  Analogon  CFT  (2 -karbomethoxy-3 -(4-fluorophenyl)-tropan),β β  
sowie das Amphetamin Methylphenidat wurden als Inhibitoren gewählt. Um aus der Vielfalt der 
erhaltenen  Positionierungen  der  Liganden  die  plausibelsten  auszuwählen,  folgten  wir  einer 
vierstufigen  Auswahlmethode:  1.  Einschränkung  der  möglichen  Posen  aufgrund  des 
Interaktionsmusters mit Hilfe des in MOE integrierten Protein Ligand Interaction Fingerprint (PLIF), 
2.  statistisches  Gruppieren  der  Posen  auf  Basis  der  räumlichen  Lage  mit  Hilfe  einer  RMSD-
Distanzmatrix, 3. Heranziehen von berechneten, energetischen Parametern für die Auswahl der 
Gruppen  und  darauf  folgende  Energieminimierung  und  4.  Auswahl  von  zwei  Posen  mit  den 
günstigsten energetischen Werten für den Protein-Ligand-Komplex.
Die  Ergebnisse  zeigen in  den jeweiligen  Gruppen,  Substrate  und  Inhibitoren,  sowohl  ähnliche 
räumliche  Orientierung  der  Posen,  als  auch  ein  ähnliches  Interaktionsmuster.  Aus  den 
vorhandenen pharmakologischen Daten und unseren Ergebnissen können wir schließen, dass die 
Bindungstaschen von Serotonin, Kokain und Methylphenidat sich überlappen. Weiters lassen die 
daten schließen, dass der Bindungsmodus von Kokain und Methylphenidat in SERT und DAT sich 
gleichen.
78
References
Adkins E. M., Barker E. L., Blakely R. D.; Interactions of Tryptamine Derivatives with Serotonin 
Transporter Species Variants Implicate Transmembrane Domain I in Substrate Recognition; Mol 
Pharmacol., 2001, 59:514–523
Al-Lazikani B., Jung J., Zhexin Xiang Z., Honig B.; Protein structure prediction; Current Opinion in 
Chemical Biology, 2001, 5:51–56
Androutsellis-Theotokis A., Goldberg N. R., Ueda K., Beppu T., Beckman M. L., Das S., Javitch J. A., 
Rudnick G.; Characterization of a Functional Bacterial Homologue of Sodium-dependent 
Neurotransmitter Transporters; J. Biol. Chem., 2003, 278:12703–12709
Baker D., Sali A.; Protein Structure Prediction and Structural Genomics; Science, 2001,  294:93-96
Barker E. L., Moore K. R., Rakhshan F., Blakely R. D.; Transmembrane Domain I Contributes to the 
Permeation Pathway for Serotonin and Ions in the Serotonin Transporter; The Journal of 
Neuroscience, 1999, 19:4705–4717
Baumann M. H., Clark R.D., Budzynski A. G., Partilla J. S., Bruce E Blough B. E., Rothman R. B.; N-
Substituted Piperazines Abused by Humans Mimic the Molecular Mechanism of 3,4-
Methylenedioxymethamphetamine (MDMA, or ‘Ecstasy’); Neuropsychopharmacology, 2005, 
30:550–560
Beuming T., Shi L., Javitch J. A., Weinstein H.; A Comprehensive Structure-Based Alignment of 
Prokaryotic and Eukaryotic Neurotransmitter/Na Symporters (NSS) Aids in the Use of the LeuT 
Structure to Probe NSS Structure and Function; Mol Pharmacol, 2006, 70:1630–1642
Beuming T., Kniazeff J., Bergmann M. L., Shi L., Gracia L., Raniszewska K., Newman A. H., Javitch J. 
A., Weinstein H., Gether U., Loland C. J.; The binding sites for cocaine and dopamine in the 
dopamine transporter overlap; Nature Neuroscience, 11:780-789
Biederman J., Spencer T.; Attention-Deficit/Hyperactivity Disorder (ADHD) as a Noradrenergic 
Disorder; Biol Psychiatry.,1999 , 46:1234 – 1242
Böhm H. J., Klebe G., Kubinyi H.; Wirkstoffdesign, Spektrum, 1996
Celik L., Sinning S., Severinsen K., Hansen C. G., Møller M. S., Bols M., Wiborg O., Schiøtt B.; 
Binding of Serotonin to the Human Serotonin Transporter. Molecular Modeling and Experimental 
Validation; JACS, 2008, 130:3853-3865
79
Chen J., Rudnick G.; Permeation and gating residues in serotonin transporter; PNAS, 2000, 97: 
1044–1049
Chen N., Reith M. E. A.; Structure and function of the dopamine transporter; European Journal of 
Pharmacology, 2000, 405:329–339
David L., Nielsen P. A., Hedström M., Norden B.; Scope and Limitation of Ligand Docking: Methods, 
Scoring Functions and Protein Targets; Current Computer-Aided Drug Design, 2005; 1:275-306
Dunbrack R. L. Jr; Sequence comparison and protein structure prediction; Current Opinion in 
Structural Biology, 2006, 16:374–384
Ermondi G., Carona G., Lawrenceb R., Longoc D.; Docking studies on NSAID/COX-2 isozyme 
complexes using Contact Statistics analysis; Journal of Computer-Aided Molecular Design, 2004, 
18:683–696
Ermondi G., Caron G.; Recognition forces in ligand–protein complexes: Blending information from 
different sources; Biochemical Pharmacology, 2006, 72:1633–1645
Faham S., Watanabe A., Besserer G. M, Cascio D, Specht A., Hirayama B. A., Wright E. M, Abramson 
J.; The Crystal Structure of a Sodium Galactose Transporter Reveals Mechanistic Insights into Na+/
Sugar Symport; Science, 2008, 321:810-814
Fain G. L.; Molecular and Cellular Physiology of Neurons, Harvard University Press, 1999
Forrest, L. R., Tavoulari S., Zhang Y., Rudnick G., Honig B.; Identification of a chloride ion binding 
site in Na/Cl-dependent transporters, PNAS; 2007, 104:12761-12766
Forrest L. R., Zhang Y, Jacobs M. T., Gesmonde J., Xie L., Honig B. H.; Rudnick G.; Mechanism for 
alternating access in neurotransmitter transporters, PNAS, 2008, 105:10338–10343
Goldstein D. S., Eisenhofer G., Kopin I. J.; Clinical Catecholamine Neurochemistry: A Legacy of 
Julius Axelrod; Cellular and Molecular Neurobiology, 2006, 26:695–702
Hardeland R.; Melatonin, hormone of darkness and more – occurrence, control mechanisms, 
actions and bioactive metabolites; Cell. Mol. Life Sci., 2008, 65:2001–2018
Henry L. K., Adkins E. M., Han Q., Blakely R. D.; Serotonin and Cocaine-sensitive Inactivation of 
Human Serotonin Transporters by Methanethiosulfonates Targeted to
Transmembrane Domain I; J. Biol. Chem., 2003, 278:37052–37063
80
Henry L. K., Field J. R., Adkins E. M., Parnas M. L., Vaughan R. A., Zou M., Newman A. H., Blakely R. 
D.; Tyr-95 and Ile-172 in Transmembrane Segments 1 and 3 of Human Serotonin Transporters 
Interact to Establish High Affinity Recognition of Antidepressants; J. Biol. Chem, 2006, 281:2012–
2023
Howell L. L., Kimmel H. L.; Monoamine transporters and psychostimulant addiction; Biochemical 
Pharmacology, 2008, 75:196–217
Huang X., Zhan C.; How Dopamine Transporter Interacts with Dopamine: Insights from
Molecular Modeling and Simulation, Biophysical Journal, 2007, 93:3627–3639
Iversen Leslie, Speed, Ecstasy, Ritalin, Oxford University Press, 2006
Iversen S. D., Iversen L. L.; Dopamine: 50 years in perspective; Trends in Neurosciences, 2006, 
30:188-193
Javitch J. A., D'Amato R. J., Strittmatter S. M., Snyder S. H.; Parkinsonism-inducing neurotoxin, N-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine 
by dopamine neurons explains selective toxicity; Proc. Nail. Acad. Sci., 1985, 82:2173-2177
Jonnakuty C., Gragnoli C.; What Do We Know About Serotonin?; J. Cell. Physiol., 2008, 217:301–
306
Kamdar G., Penado K. M. Y., Rudnick G., Stephan M. M.; Functional Role of Critical Stripe Residues 
in Transmembrane Span 7 of the Serotonin Transporter; Journal of Biological Chemisty, 2001, 
276:4038–4045
Kaufmann K. W., Dawson E. S., Henry L. K., Field J. R., Blakely R. D., Meiler J.; Structural 
determinants of species-selective substrate recognition in human and Drosophila serotonin 
transporters revealed through computational docking studies; published online: 14 Aug 2008
Kelkar S. V., Izenwasser S., Katz J. L., Klein C. L., Zhu N., Trudell M. L.; Synthesis, Cocaine Receptor 
Affinity, and Dopamine Uptake Inhibition of Several New 2p-Substituted 38-Phenyltropanes; J. Med. 
Chem., 1994, 37:3875-3877
Kitchen D. B., Decornez H., Furr J. R., Bajorath J.; Docking and Scoring in Virtual Screening for Drug 
Discovery: Methods and Applications; Nature Reviews, 2004, 3:935-349
Kline, R. H, Jr., Eshleman A. J, Wright J., Eldefrawi M. E.; Synthesis of Substituted 3-
Carbamoylecgonine Methyl Ester Analogues: Irreversible and Photoaffinity Ligands for the Cocaine 
Receptor/Dopamine Transporter; J. Med. Chem., 1994, 37:2249-2252
81
Leach A. R., Shoichet B. K., Peishoff C. E.; Docking and Scoring: Perspective - Prediction of Protein-
Ligand Interactions. Docking and Scoring: Successes and Gaps; 2006, 49:5851-5855
Lee D., Redfern O., Orengo C.; Predicting protein function from sequence and structure; Nature 
Reviews, 2007, 8:995-1005
Lesk A. M.; Introduction in Protein Architecture, Oxford University Press, 2001
Löffler G.; Basiswissen Biochemie, Springer Verlag, 2001
Madras B. K. (Editor); Cell Biology of Addiction, Cold Spring Harbour Laboratory Press, 2006
Martí-Renom M. A., Stuart A. C., Fiser A., Sánchez R., Melo F., Sali, A.; Comparative Protein 
Structure Modeling of Genes and Genomes; Annu. Rev. Biophys. Biomol. Struct., 2000, 29:291–325
Masson J., Sagné C., Hamon M., El Mestikawy S.; Neurotransmitter Transporters in the Central 
Nervous System; Pharmacological Reviews, 1999, 51:439-464
Meltzer P. C., Wang P., Blundell P., Madras B. K.; Synthesis and Evaluation of Dopamine and 
Serotonin Transporter Inhibition by Oxacyclic and Carbacyclic Analogues of Methylphenidate; J. 
Med. Chem., 2003, 46:1538-1545
Moult J.; A decade of CASP: progress, bottlenecks and prognosis in protein structure prediction; 
Current Opinion in Structural Biology, 2005, 15:285–289
Mutschler E; Arzneimittelwirkungen, WVG, 2001
Nonaka R., Nagai F., Ogata A., Satoh K.; In Vitro Screening of Psychoactive Drugs by [35S]GTPg S 
Binding in Rat Brain Membranes; Biol. Pharm. Bull., 2007, 30:2328-2333
Petsko G. A., Ringe D. (Editors); Protein Structure and Function, Sinauer Associates, 2004
Petrey D., Honig B.; Protein Structure Prediction: Inroads to Biology; Molecular Cell, 2005, 20: 811–
819
Pschyrembel W.; Klinisches Wörterbuch; WdeG, 2001, 259. Auflage
Quick M. W. (Editor); Transmembrane Transporters, Wiley-Liss, 2002
82
Quick M., Yano H., Goldberg N. R., Duan L., Beuming T., Shi L., Weinstein H., Javitch J. A.; State-
dependent Conformations of the Translocation Pathway in the Tyrosine Transporter Tyt1, a Novel 
Neurotransmitter:Sodium Symporter from Fusobacterium nucleatum; J Biol Chem, 2006, 
281:26444-26454
Rauhut R.; Bioinformatik, Wiley-Vch, 2001
Rothman R. B., Baumann M. H.; Monoamine transporters and psychostimulant drugs; European 
Journal of Pharmacology, 2003, 479:23–40
Rothman R. B., Baumann M. H., Prisinzano T. E., Newman A. H.; Dopamine transport inhibitors 
based on GBR12909 and benztropine as potential medications to treat cocaine
addiction; Biochemical Pharmacology, 2008, 75:2–16
Rudnick G.; Bioenergetics of Neurotransmitter Transport; Journal of Bioenergetics and 
Biomembranes, 1998, 30:173-185
Rudnick G., Serotonin Transporters – Structure and Function; J. Membrane Biol., 2006, 213:101–
110
Saier M. H. Jr; Genome archeology leading to the characterization and classification of transport 
proteins; Current Opinion in Microbiology, 1999, 2:555–561
Schultes E., Hofmann A.; Pflanzen der Götter, AV, 1998
Shi L., Quick M., Zhao Y, Weinstein H., Javitch J. A.; The Mechanism of a Neurotransmitter:Sodium 
Symporter - Inward Release of Na+ and Substrate Is Triggered by Substrate in a Second Binding 
Site; Molecular Cell, 2008, 30:667–677
Shulgin A., Shulgin A.; PIHKAL - a chemical love story, Transform Press, 1995
Siegel, G.J., Agranoff, B.W., Albers, R.W., Molinoff, P.B. (Editors); Basic Neurochemistry, Raven 
Press, 1994
Singh S. K., Yamashita A., Gouaux E.; Antidepressant binding site in a bacterial homologue of 
neurotransmitter transporters; Nature Letters, 2007, 448:952-956
Snyder S. H.; Chemie der Psyche - Drogenwirkung im Gehirn, Spektrum, 1990
Steger G.; Bioinformatik, Birkhäuser, 2003
83
Storch A., Ludolph A. C., Schwarz J.; Dopamine transporter: involvement in selective dopaminergic 
neurotoxicity and degeneration; J Neural Transm, 2004, 111:1267–1286
Swanson J. M., Volkow N. D.; Serum and brain concentrations of methylphenidate:implications for 
use and abuse; Neuroscience and Biobehavioral Reviews, 2003, 27:615-621
Thews, G., Mutschler, E., Vaupel, P. (Editors); Anatomie, Physiologie, Pathophysiologie des 
Menschen, WVG, 1999
Torres G. E., Gainetdinov R. R., Caron M. G.; Plasma Membrane Monoamine Transporters: 
Structure, Regulation and Function; Nature Reviews Neuroscience, 2003, 4:13-25
Whitaker-Azmitia P. M.; The Discovery of Serotonin and its Role in Neuroscience; 
Neuropsychopharmacology, 1999, 21
White K. L., Kiser P. D., Nichols D. E., Barker E. L.; Engineered zinc-binding sites confirm proximity 
and orientation of transmembrane helices I and III in the human serotonin transporter; Protein Sci., 
2006, 15:2411-2422
Xhaard H., Backstrom V., Denessiouk K., Johnson M. S.; Coordination of Na+ by Monoamine 
Ligands in Dopamine, Norepinephrine, and Serotonin Transporters; J. Chem. Inf. Model advanced 
online
Yamashita A., Singh S. K., Kawate T., Jin Y., Gouaux E.; Crystal structure of a bacterial homologue 
of Na/Cl-dependent neurotransmitter transporters; Nature, 2005, 437:215-223
Zhou Z., Zhen J., Karpowich N. K., Goetz R. M., Law C. J., Reith M. E. A., Wang D.; LeuT-Desipramine 
Structure Reveals How Antidepressants Block Neurotransmitter Reuptake; Science, 2007, 
317:1390-1393
Zomot E., Bendahan A., Quick M., Zhao Y, Javitch J. A., Kanner B. I; Mechanism of chloride 
interaction with neurotransmitter:sodium symporters; nature letters, 2007, 1-6
84
Links
The Protein Database http://www.rcsb.org
Swissprot http://www.expasy.org
The Chemical Computing Group http://www.chemcomp.com
Isis Draw http://www.mdli.com
Cooperation partners:
homepage of Dr. Gerhard F. Ecker http://homepage.univie.ac.at/Gerhard.F.Ecker
Medical University of Vienna http://www.meduniwien.ac.at/pharmakologie
SFB35 http://www.sfb35.at
Contact:
All files are available from René Weissensteiner (rene@dekor.cc) and Gerhard F. Ecker 
(gerhard.f.ecker@univie.ac.at).
85
Curriculum vitae
Persönliche Daten:
Name René Weissensteiner
Geburtstag 2. November 1978
Familienstand ledig, verlobt mit Martina Gall, 
gemeinsame Tochter Sophie Katharina (* 8.10.2006, † 12.2.2008)
Ausbildung:
1985 – 1989: Volksschule II in Tulln
1989 – 1993: Hauptschule III in Tulln
1993 – 1994: HTBLuVA St. Pölten, Abteilung EDV und Organisation
1994 – 1999: Handelsakademie St. Pölten, Matura im Juni 99
seit Oktober 1999: Studium der Pharmazie an der Universität Wien,
Februar 2002: Sprachreise México
Jänner 2004: 1. Diplomprüfung
Februar 2005: Botanische Exkursion Costa Rica
seit Oktober 2007: Diplomarbeit Pharmakoinformatik
Arbeitstätigkeit
Juli 1994: Ferialpraxis, Leitzinger GmbH
Sommer 95, 96, 98, 2000: Ferialarbeit, Brucha GmbH
Okt. 2000 – Okt. 2001: Zivildienst, Emmausgemeinschaft St. Pölten
September 2002: Ferialpraxis, Apotheke Pöggstall, NÖ
Nov. 2002 – Jan. 2004: geringfügig beschäftigt, Apotheke A. Moll, Wien 1
Juli/August 2003: Ferialarbeit, Brucha GmbH
September 2004: Ferialpraxis, in Apotheke Pöggstall, NÖ
Okt. 2005 – Jun. 2006: geringfügig beschäftigt, Hellrein GmbH
Okt. 2006 - Feb. 2007: Karenz
seit Oktober 2007: Tätigkeit als Schlagzeuglehrer
Sonstiges / Hobbies:
Musik, erlerne Schlagzeug und Perkussion seit 1993, Gitarre und Klavier 
autodidaktisch, musikalische Tätigkeit in verschiedenen Gruppen und Musikvereinen
Fotografie und digitale Medien
Sport und Reisen, ausgedehnte Aufenthalte in der Natur
Wissenschaftliche Literatur
86
